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Abstract
Ischemic preconditioning (IPC) is a defensive adaptive cellular phenomenon. Brief ischemic stimuli render the heart
resistant to subsequent similar stress. Signaling for IPC and pharmacologically induced preconditioning involves
several G-protein coupled cell surface receptors, second messengers, speciﬁc Ser-Thr-protein kinase-C isoforms,
Tyr-kinases, and ﬁnally, results in activation of ATP-dependent potassium channels (inward rectiﬁers) at the
sarcolemma and in the mitochondria. In cardiomyocytes these channels regulate cytosolic and mitochondrial Ca2+
levels. K+ inﬂux into mitochondria proves to be a key factor for keeping the mitochondrial permeability transition
pore closed. This ensures continuous energy production and prevents cell death by apoptosis or necrosis. Molecular
structure, function, and pharmacological properties of the ATP-dependent potassium channels and of the
mitochondrial permeability transition pore are discussed. Channel activating agents mimic IPC and also aﬀect
reactive oxygen species producing enzymes involved in mitochondrial respiration. Volatile anesthetics, among other
drugs, mimic the cardioprotective eﬀects of IPC. Their intracellular signaling and clinical application are brieﬂy
discussed.
Introduction: Cytoprotective potential of cardiac
preconditioning
Cardiac preconditioning (PC) represents a potent and
reproducible method to render the myocardium more
resistant against irreversible structural and functional
damage induced by a variety of noxious stimuli. The
phenomenon of ischemic preconditioning (IPC) was ﬁrst
described in 1986 (Murry et al., 1986) in the canine
myocardium. By subjecting the heart to four brief
ischemic episodes by using ligation of the circumﬂex
coronary artery, interspersed with brief episodes of
reperfusion before a prolonged ischemic insult (40 min),
the tolerance against cellular injury was increased and
the infarct size (necrosis) was signiﬁcantly reduced from
29 to 7% in the myocardial area at risk. The area at risk
encompasses tissue, the blood supply of which comes
from the ligated artery and has no compensatory supply
by collateral vessels. Without PC, total occlusion of a
coronary artery will cause irreversible myocardial dam-
age and cell death within approximately 20 min (Jen-
nings and Reimer, 1991). Interestingly, in most animal
studies IPC proved to oﬀer a degree of protection
equivalent to prevent cell death by about an additional
20 min (Lawson and Downey, 1993). Several years after
the description of acute cardiac protection by IPC, a
second delayed window of protection was observed
(Marber et al., 1993). The ﬁrst acute or early phase of
protection develops within minutes after IPC and lasts
for 1–3 h. The second or late phase of protection
appears 12–24 h after the ﬁrst phase has subsided, and
lasts for 3–4 days before it fades away (Bolli, 2000).
Although the extent of protection in the late phase does
not reach the degree of protection during the shorter
ﬁrst phase, it is this longer lasting protective period that
may be of particular therapeutic interest for patients
with coronary artery disease (CAD).
The endogenous cardioprotective mechanism of IPC
could be conﬁrmed in almost all species including
mouse, rat, guinea pig, rabbit, dog and pig (Yellon
et al., 1998). In addition, IPC was also observed in
single cells (Marber, 2000), in superfused myocardial
specimens (Walker et al., 1995), and in isolated hearts in
vitro. In the past 16 years, the literature exploded with
over 4000 published reports on this topic. Under most
experimental conditions, IPC restricts infarct size, im-
proves postischemic contractile function and reduces
arrhythmias. IPC not only aﬀords protection against
loss of function and necrosis but also against the
programmed, energy-dependent cell death called apop-
tosis (Piot et al., 1997). All these ﬁndings elicited great
interest in the preconditioning process for a possible
therapeutic use. Indeed, signs of naturally occurring IPC
in patients with CAD has been inferred from observa-
tions that preinfarction angina reduces myocardial
infarct size, improves ventricular function and reduces
arrhythmias (Hirai et al., 1992; Nakagawa et al., 1995;
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Ottani et al., 1995). The authors concluded that the
anginal episodes (presumably repetitive brief ischemias)
preconditioned the heart for the impending coronary
occlusion. In addition, repetitive aortic cross-clamping
during coronary artery bypass grafting (CABG) as well
as coronary artery ballon inﬂations during percutaneous
transluminal coronary angioplasty (PTCA) may serve as
preconditioning stimuli (Deutsch et al., 1990; Yellon
et al., 1993). Although prophylactic induction of IPC
cannot be applied routinely in patients with CAD to
avert impending myocardial infarction (MI), it would be
desirable to employ it in the clinical setting, particularly
the perioperative period. With increasing life expectancy
and improved surgical techniques an ever larger number
of elderly patients with cardiovascular disease or risk
factors thereof undergo cardiovascular and general
surgery. 10–18% of high-risk patients undergoing sur-
gery will suﬀer from perioperative cardiovascular com-
plications including MI (Raby et al., 1989; Mangano
et al., 1990).
Investigations into the mechanisms of IPC lead to the
observation that various pharmacological agents may
elicit preconditioning-like eﬀects in experimental ani-
mals (Nakano et al., 2000). Thus, pharmacological
preconditioning (PPC) could provide a safer way than
ischemia for inducing cardioprotection in humans.
Results from experimental animal models and similar
observations in clinical studies indicate that adenosine
receptors, protein kinase-C (PKC), and mitochondrial
ATP-sensitive potassium channels (mitoK-ATP chan-
nels) may be involved in the pharmacologically induced
preconditioning process (reviewed by Nakano et al.,
2000). Great eﬀorts are ongoing to delineate the
intracellular signaling pathways, which relay the surface
receptor stimuli to the target sites, and to elucidate the
cytoprotective mechanisms. Anesthetics represent one
class of drugs with potential cardioprotective properties
(Zaugg et al., 2003b). Infarct-limiting properties of
volatile anesthetics were reported as early as 1983
(Davis et al., 1983; Davis and Sidi, 1989). We now
know that many anesthetics elicit, enhance, or inhibit
the preconditioned state (Zaugg et al., 2002a). The use
of cardioprotective anesthetics, which can be adminis-
tered systemically with low toxicity, represents a desir-
able concept, particularly for high-risk cardiac patients
undergoing surgery.
The following aspects of PC will be dealt with in this
review: (i) time-relation of early and delayed PC; (ii) PC
trigger stimuli such as ischemia-reperfusion, stress-
stimuli, and pharmacological agents; and (iii) PC
protection against cell death (necrosis and apoptosis),
cellular dysfunction (including stunning and hiberna-
tion), and arrhythmias. Special focus concerns the
signaling and cellular mechanisms for cardioprotection
aﬀorded by IPC and PPC with special reference to new
insights on anesthetic preconditioning (APC). Due to
the wide area covered, reviews containing references to
primary literature are often cited. This also helps the
newcomer to acquire a balanced overview on this ﬁeld.
Cell damage by ischemia-reperfusion injury
Limited supply of oxygen and metabolic substrates
because of a reduced blood ﬂow to the myocardium,
causes metabolic, functional, and morphological chan-
ges. This is coupled with a restricted washout and
accumulation of ions and metabolites as well as a shift
from aerobic to anaerobic metabolism. Reduced energy
production results in depletion of the immediate cellular
energy stores, ATP and creatine phosphate (CrP).
Consequently, contractile function and energy-depen-
dent ion pumps (Ca2+-ATPase of sarcoplasmic reticu-
lum and sarcolemmal Na/K-pump) are depressed
(Jennings et al., 1991). The resulting increase in cytoso-
lic Na+ and Ca2+ with a concomitant loss of intracel-
lular K+ aﬀects transmembrane ion gradients and the
membrane potential. These alterations lead to an
accumulation of catabolites and byproducts, to acidosis,
increased osmotic load, production of reactive oxygen
species (ROS), and activation of various Ca2+-sensitive
enzymes. At this point morphological changes are
beginning to occur. Activated proteases start degrading
myoﬁbrillar and cytoskeletal proteins while lipases may
aﬀect phospholipids in the membranes. The ensuing
rupture of the cell membrane will ultimately cause
cellular death (Sommerschild and Kirkeboen, 2002).
As long as the myocyte has not died during ischemia,
one would expect that, upon reperfusion, it is going to
recover. Reperfusion, however, adds further strain onto
the cell. The return of oxygen and nutrients with
reperfusion allows the cardiomyocyte to resume energy
production. The cytosolic Ca2+, already high in the
ischemic period, may further increase during the early
reperfusion phase by entering the cell via the voltage-
sensitive Ca-channels (L-type Ca-channel) of the sarco-
lemma, the Na/Ca-exchanger as well as by Ca2+ release
from the intracellular sarcoplasmic reticulum (SR) (Du
Toit and Opie, 1992; Kusuoka et al., 1993). In addition,
stimuli triggered by primary messengers such as angio-
tensin-II, endothelin, catecholamines, cytokines and
polysaccharides, which accumulate during the ischemic
period, are expected to interfere with the orderly
coordination of energy production and its usage by
ion pumps and the contractile machinery (Brunner
et al., 1993; Gao et al., 1995; Opie, 1997). Reperfusion
arrhythmias due to cytosolic Ca2+-transient oscillations
(Du et al., 1995) and overstimulation of the tricarboxy-
lic acid cycle (TCAC) because of increased mitochond-
rial Ca2+ (McCormack, 1985), result from a lack of tight
control over intracellular signaling coordination. Final-
ly, the Ca2+ overload may lead to a particularly
cytotoxic burst of ROS production.
Taken together, during ischemia-reperfusion the car-
diomyocytes are exposed to a sequence of adaptive and
injurious events. In principle, two components can be
discerned, one that develops during ischemia (ischemic
injury) and a second one, which develops during
reperfusion (reperfusion injury). The term ‘reperfusion
injury’ is in fact a misnomer, because it is the severity of
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ischemia that sets the stage for the development of
reperfusion injury, and the appropriate term should be
‘ischemia-reperfusion injury’ (Bolli and Marban, 1999).
Experimental data indicate that the damage caused by
the reperfusion component is always larger than the one
caused by ischemia alone. However, the degree of
damage caused by the reperfusion component is posi-
tively related to the degree of the antecedent ischemic
component. Consequently, pharmacological interven-
tions that alleviate the underlying ischemic component
of injury (e.g. adenosine, Ca-channel blockers, volatile
anesthetics, K-ATP channel openers, abbreviated
KCOs) will also indirectly reduce the inevitable damage
caused by the reperfusion component. In addition,
diﬀerent areas of the myocardium may be more or less
severely strained, depending on the duration and degree
of restricted blood supply. Correspondingly, the myo-
cytes may acquire diﬀerent states of reversible and
irreversible damage.
Necrosis and apoptosis, both occurring concurrently?
The predominant cause for early cell death in both
ischemia and reperfusion appears to be the mechanical
disruption of the sarcolemma. As mentioned above,
during ischemia lasting for more than 20 min, the
increased cytosolic Ca2+ induces enzymatic degradation
of structural elements. On the other hand, in the early
reperfusion phase mechanical disintegration of the
cellular entity may occur for the following two reasons:
(i) myocyte hypercontracture induced by the re-energi-
zation while cytosolic Ca2+ is still high (this phenom-
enon has been called ‘oxygen paradox’), and (ii) swelling
of the cell by water uptake when intracellular osmolality
is still high, while the extracellular osmolality diminishes
fast upon reperfusion (Piper et al., 1998). Cell debris in
the necrotic area may provoke proliferative inﬂamma-
tion leading to scar development.
Apoptosis, in contrast, is an energy-dependent process
occurring after some delay and represents a transcrip-
tionally regulated response to moderate cell injury or to
the inﬂuence of various cytokines. It is characterised by
shrinkage of the cell, condensation of chromatin, frag-
mentation into membrane-bound apoptotic bodies and
rapid phagocytosis by neighbouring cells without induc-
tion of inﬂammatory response (Narula et al., 2000; Zhao
and Vinten-Johansen, 2002). The apoptotic death path-
way becomes irreversible when the endonucleases are
activated to degrade the genomic DNA at internucleo-
somic loci. Although evidence for apoptosis in ischemic-
reperfused myocardium and in the border zones of MI
has been demonstrated, it is still under debate whether
the number of apoptotic cells contributes signiﬁcantly to
the extent of loss of functional tissue after acute
ischemia-reperfusion injury. The necrotic process is
completed in roughly 24 h and apoptosis within nearly
4 h leaving no traces. Thus, the extent of the contribu-
tion of apoptosis to cell death may be largely underes-
timated (Anversa and Nadal-Ginard, 2002).
While the extent of necrosis is routinely assessed by
vital staining with triphenyltetrazolium chloride (TTC),
DNA nick end-labeling (TUNEL staining) is taken as
an index for apoptosis, which however, requires conﬁr-
mation by electrophoretic display of the discrete DNA
fragments (DNA laddering) and electron microscopic
identiﬁcation of apoptosis-related cell structures. The
level of TUNEL-positive myocyte nuclei is very low in
healthy hearts (below 0.002% or not detectable at all).
Myocyte apoptosis was shown to occur in ischemia-
reperfusion damaged myocardium in animal models and
in human infarct tissue (for references see Palojoki et al.,
2001). Apoptosis was also found in viable myocardial
areas after MI, in experimental and also in human
ischemic heart failure. Under prolonged ischemia in-
duced by coronary artery occlusion in rat and dog
models, few TUNEL-positive cells (0.5–1.0%) and no
DNA laddering was observed in the infarct area, while
in the infarct border zone TUNEL-positive cells in-
creased up to 20–30% after one hour of ischemia
followed by 6 h of reperfusion (Zhao and Vinten-
Johansen, 2002). Under the latter conditions, the ne-
crotic infarct size peaked at around 24 h and remained
constant thereafter, while the number of TUNEL-
positive cells in the peri-necrotic zone progressively
increased up to 50–60% over the following days and was
accompanied by increased DNA laddering. In areas
remote from MI the TUNEL-positive myocyte levels
were also increased up to 1% as compared to 0.002% in
undisturbed hearts. These data suggest that necrosis
develops early during reperfusion and is followed by a
slower appearance of TUNEL-positive cells in the
infarct border zone accounting for a dynamic processing
of cell death with concomitant loss of functional
myocardium.
Three particular aspects warrant special consider-
ation. First, TUNEL-positive myocytes in biopsies from
hearts of patients with dilative cardiomyopathy (DCM)
at end-stage failure were shown to exhibit no ultrastruc-
tural characteristics of apoptosis (Kanoh et al., 1999).
Almost all TUNEL-positive nuclei also stained positive
for proliferating cell nuclear antigen, suggesting the
presence of DNA in these nuclei being processed for
either repair or replication. Replication was excluded,
however, by negative nuclear staining for the replica-
tion-speciﬁc antigen Ki-67. In addition, the Taq poly-
merase-based DNA in situ ligation assay, which
speciﬁcally detects double-stranded DNA breaks with
single-base 3¢-overhang in cells undergoing apoptosis,
was negative in all cases. In conclusion, TUNEL-
positive staining may evidence nuclei with active DNA
in the process of repair, while nuclear apoptosis still
being scarce. Second, the apoptotic process is mediated
by activation of caspases (cysteine aspartases) that
cleave cytosolic proteins and nuclear targets. The
processing of caspases proceeds along two major path-
ways (Narula et al., 2000; Zhao and Vinten-Johansen,
2002). One pathway is initiated by binding of extracel-
lular ligands (Fas ligand, TNF-a) to their cell surface
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receptors leading to caspase-8 activation (Borutaite
et al., 2003). The other pathway is receptor-independent
and involves stress signals including ischemia-reperfu-
sion, hypoxia-reoxygenation, calcium overload, and
mechanical stretch, all inducing release of cytochrome-
c from mitochondria into the cytoplasm. Cytochrome-c
is a respiratory chain protein that contributes to
oxidative phosphorylation and energy production. It
was recently shown that the two pathways may not be
mutually exclusive and that cytokines also lead to the
release of cytochrome-c, which activates caspase-3 (Luo
et al., 1998). Caspase-3 degrades cytosolic substrates
such as troponin-C (TnC), PKCdelta and probably
others, as well as nuclear substrates including poly
(ADP-ribose) polymerase (PARP). Caspase-3 is the
primary initiator of apoptotic DNA fragmentation by
proteolytically inactivating DFF45/ICAD, which relea-
ses the active DFF40/CAD endonuclease that preferen-
tially attacks chromatin in the internucleosomal linker
DNA (Wolf et al., 1999). Release of cytochrome-c from
mitochondria thus represents a key step in mediating
apoptosis.
The mitochondrial apoptotic signaling pathway ope-
rates via the formation of a trimeric complex of
liberated cytochrome-c with the apoptotic proteinase
activating factor-1 (APAF1) and procaspase-9 (Zhao
and Vinten-Johansen, 2002). This complex is instru-
mental in activating caspase-3, but it is itself under the
control of a number of intracellular apoptosis regulating
proteins: the Bcl2 protein family (B-cell leukemia/
lymphoma2-like proteins). The Bcl2 family is composed
of of a group of anti-apoptotic proteins (Bcl2, BclXL,
Bclw, Bag1 and BI1) that, when overexpressed, attenu-
ate the expression of a group of pro-apoptotic proteins
(Bax, Bak, Bad, Bid and Bim). In addition, the tumour
suppressor DNA-binding transcription factor p53 was
recently shown to act as an intermediate eﬀector of
apoptosis by either activating the transcription of death
proteins (Bax) or suppressing the transcription of
survival proteins (Bcl2), or both (MacLellan and Schnei-
der, 1997). In isolated beating rat hearts, ischemia
without reperfusion did not induce apoptosis or alter the
appearance of apoptosis regulating proteins, whereas, a
short period of ischemia followed by reperfusion in-
duced a time-dependent reduction in the expression of
the Blc2 protein and an increase in the expression of Bax
and p53 proteins (Zhao and Vinten-Johansen, 2002).
Third, an additional apoptotic pathway independent
of caspases, requires Ca2+-activation of calpain (an
unbiquitously expressed cytosolic cysteine-proteinase)
with consequential mitochondrial dysfunction (Chen
et al., 2002). Postischemic reperfusion of isolated hearts
results in sodium inﬂux into the myocytes followed by
Ca2+ accumulation. This leads to calpain activation,
which in turn leads to cleavage of Bid. Activated Bid
targets the mitochondria, causing dysfunction and
release of factors, which commit the cell to death, such
as cytochrome-c, Smac/DIABLO, pro-caspases, apop-
tosis-inducing factor (AIF), and endonuclease-G. The
loss of cytochrome-c results in inhibition of oxidative
phosphorylation, increased production of ROS and
irreversible opening of the mitochondrial permeability
transition pore (mitoPTP).
Taken together, the apoptotic process in cardiomyo-
cytes seems to be triggered primarily by ROS originating
during reperfusion after ischemia. In the heart, however,
the process seems to diﬀer from classic apoptosis in as
much as cytosolic structures become degraded while the
nuclei are partially preserved retaining their DNA repair
capacity. Most cardiomyocytes with ultrastructural
evidence of released cytochrome-c and activated cas-
pase-3 exhibited intact nuclei in specimens from failing
human hearts. One may speculate that the terminally
diﬀerentiated cardiomyocytes evolved mechanisms for
the nuclei to resist fragmentation despite of the contin-
ued cytoplasmic apoptosis (Narula et al., 2001). Because
apoptosis is an energy requiring process, it is conceiv-
able that a portion of the cells, which entered the
apoptotic pathway and have depleted their energy stores
during ischemia, may follow the necrotic death pathway.
It seems equally plausible, but proves diﬃcult for
experimental conﬁrmation, that some of the non-lethally
aﬀected myocytes can recover and resume functionality
after a steady supply of oxygen and nutrients has been
re-established. Finally, it may be concluded that during
reperfusion a signiﬁcant number of myocytes enters the
apoptotic pathway, predominantly in the infarct border
zone, concurrently with areas of necrosis, whereby their
fate remains open for some time before it turns for the
better or the worse.
Postischemic contractile dysfunction
The contractile dysfunction of myocytes that have
survived ischemia-reperfusion may, even after restora-
tion of the blood supply, persists for hours or days
before it recovers completely. This postischemic myo-
cardial dysfunction has been originally observed in dogs
after brief coronary artery occlusion (Heyndrickx et al.,
1975) and was later termed ‘myocardial stunning’
(Braunwald and Kloner, 1982). The stunning phase
may be characterised by the perfusion-function mis-
match, i.e., normal blood supply combined with reduced
contractility. Myocardial stunning can be elicited in
various ways: (i) after a single ischemic episode lasting
not longer than about 15 min, (ii) after multiple short
ischemic episodes interspersed by reperfusions, (iii) after
partial reversible ischemia due to subendocardial infarc-
tion, or (iv) after strenuous exercise causing so-called
‘high-ﬂow ischemia’ (Bolli and Marban, 1999). In the
latter condition, the cardiac vascular system cannot
provide suﬃcient oxygen to the myocardium under
increased hemodynamic workload. The primary prob-
lem is an increase in oxygen demand rather than a
decrease in supply.
The underlying pathophysiological etiology for stun-
ning seems to depend on increased ROS and cytosolic
Ca2+, both occurring during ischemia and further
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augmented during reperfusion. Although the precise
mechanism that induces the typical perfusion-function
mismatch, has not yet been identiﬁed, it is now accepted
that the increased Ca2+ level is critical for stunning (for
more references see Papp et al., 2000). The intracellular
Ca2+-dependent calpain is believed to be responsible for
degradation of myoﬁbrillar and cytoskeletal proteins
including troponin-I (TnI), titin, myosin, myosin bind-
ing protein-C (MyBPC), microtubules, spectrin, alpha-
actinin and desmin. Degradation of most of these
proteins as well as contractile deterioration can be
prevented in in vitro experiments by application of the
protease inhibitor calpstatin. In addition, covalent
troponin complexes, binding of cytosolic glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) and
alphaB-crystalline (a myocardial stress protein) to
myoﬁbrils were also blamed for aﬀecting Ca2+-sensitiv-
ity and deterioration of contractile parameters in
stunned myocytes.
In contrast to stunning, myocardial hibernation
describes a state in which the reduced contractile
function is accompanied (i.e. ‘matched’ instead of
‘mismatched’ in stunning) by a reduced oxygen con-
sumption (Sherman et al., 1997). Hibernation may be
induced by reduced coronary ﬂow over one to several
hours, or alternatively, it may result from repetitive
episodes of stunning, which have a cumulative eﬀect and
cause protracted postischemic dysfunction (Heusch
et al., 1997). The term hibernation comes from the
zoology vocabulary and describes a state of reduced
activity in a situation of reduced energy supply. In the
context of CAD, myocardial hibernation was originally
interpreted as a chronic, adaptive reduction of contrac-
tile function in response to a reduction of myocardial
blood supply. In both stunning and hibernation, the
myocardium is in a state of preservation with sublethal
cell damage, from which it may recover completely,
rather than turn into necrosis. Despite their distinct
deﬁnition, stunning and hibernation may merely repre-
sent transitional states in a continuum extending from
unimpaired functional tissue to irreversible necrosis.
These myocardial tissue areas with recoverable function,
would beneﬁt most from therapeutical measures such as
interventional reperfusion or surgical revascularisation.
As mentioned above, acute IPC may elicit stunning,
while PPC usually reduces the extent of stunning
(Przyklenk and Kloner, 1998). Some variability in the
eﬀects of acute PC may depend on the experimental
conditions and may also reﬂect species diﬀerences. In
the delayed phase of PC stunning is always reduced
irrespective of the type of stimulus.
Preconditioning as adaptation to tissue injury?
A decisive role for the survival of myocardial tissue in
the area of an occluded artery also plays the collateral
vessel connections to the neighbouring areas (vascular
channels that interconnect arteries), the perfusion of
which is still suﬃcient (Schaper et al., 1988). Such a
collateral circulation is almost absent in the hearts of
mice, rats, rabbits and pigs, it is intermediately estab-
lished in the hearts of dogs and humans, and extensively
present in guinea-pig hearts. Accordingly, the infarct
size induced under deﬁned experimental conditions is
most reproducible in those animals with little collateral
circulation, and virtually no infarction develops in
guinea-pigs under acute coronary occlusion.
PC may be considered to represent a general adaptive
process for cell protection which can be elicited by,
beside ischemia, diﬀerent stress-stimuli such as hypoxia,
free radicals, mechanical stretch, thermal stress and
endogenous primary messengers (vasoactive peptides,
catecholamines and hormones) (Schulz et al., 2001;
Sommerschild and Kirkeboen, 2002). As long as a
perturbation stimulus remains sublethal, the cell will not
only recover its original state, but will emerge in a
strengthened one to fend oﬀ further harm. It seems
paradoxical that a sublethal ischemia is able to protect
the myocardium from subsequent potentially lethal
sustained ischemia. For the individual cell the IPC
process means a tightrope walk with an uncertain
outcome of survival.
Myocardial preconditioning induced by anoxia has
been observed in rainbow trout hearts, which are
normally extremely hypoxia intolerant (Gamperl et al.,
2001). The time course and magnitude of loss of
myocardial function during acute anoxia is similar in
the trout and the rabbit. These results suggest that PC is
a mechanism of tissue protection that preceded the
evolution of marine and terrestrial vertebrate life 300–
400 million years ago in the mid paleozoic (Ayala et al.,
1998). In addition, ischemia in organs other than heart
can also aﬀord protection of the myocardium (Som-
merschild and Kirkeboen, 2002). This eﬀect is called
‘remote PC’ and is probably caused by neurogenic
activation and/or circulating hormones. It was indeed
shown that IPC confers protection to both the endo-
thelial and smooth muscle cells of the vascular system
and that, consequently, most hypoxia-sensitive organs
like the brain, intestines, liver and kidney receive PC
trigger stimuli (Rubino and Yellon, 2000; Laude et al.,
2002; Torras et al., 2002). Whether unicellular eukar-
yotes also possess the capacity for PC is not known. One
may speculate that for PC a multicellular organism with
a systemic circulation is required, which ensures the
transport of primary messengers to the whole body.
In vitro models for preconditioning
The isolated beating heart started work in 1895
For the delineation of PC triggers and signaling path-
ways isolated cardiomyocytes in culture with a deﬁned
medium have proven suitable (Jacobson and Piper,
1986; Schaub et al., 1997; Marber, 2000). This allows to
develop experimental conditions for testing individual
steps in a signaling cascade under stimulation with
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primary messengers such as catecholamines, hormones,
vasoactive peptides or drugs, without signaling interfer-
ence from other cell types (ﬁbroblasts, vascular endo-
thelial and smooth muscle cells, and neurons). The
myocytes comprise around 80% of the heart mass but
represent only 35% of the total cell number (Korecky
and Rakusan, 1978). A second crucial step consists in
establishing the link between a distinct signaling path-
way and a speciﬁc cellular response. Beside isolated
cells, tissue strips and papillary muscles in culture
systems, the intact beating heart is particularly suited
for measuring functional parameters be it in situ or as
isolated organ in the Langendorﬀ apparatus. The
isolated perfused heart has the advantage that external
variables, unlike in the in situ situation, may be readily
standardised with respect to temperature, pH, ion
concentrations, energy substrates and drugs. Since the
ﬁrst description by Langendorﬀ (1895), the isolated
perfused heart is still the ﬁrst choice model for studying
the eﬀects of IPC and PPC on contractile function
together with ECG, coronary ﬂow, metabolic, biochemi-
cal, and immunohistochemical parameters.
Figure 1 shows the contractility recordings of isolated
rat hearts in the Langendorﬀ setting comparing the
eﬀects on contractile recovery during the reperfusion
phase after the test ischemia alone or with prior IPC and
APC by isoﬂurane, a commonly used volatile anesthetic.
Both IPC and APC signiﬁcantly improve the contractile
recovery during the reperfusion phase. With APC the
original extent of ventricular pressure development is
reached after 30 min of reperfusion. Beyond that time
point the hearts having received APC perform as well as
controls without ischemic challenge. Almost as soon as
perfusion is stopped (at the beginning of the test
ischemia), cardiac contracture starts. Not only systolic
contraction but also diastolic relaxation recovers faster
and more completely during reperfusion with prior PC,
and particularly so with APC (Figure 1B, C and D).
Rapid decline of ATP and cytosolic Ca2+ overload
contribute to the contracture during zero-ﬂow even
when it lasts only for 5 min during IPC. Complete
oxidation of 1 mol of glucose yields 36 mol of ATP. In
the absence of oxygen supply, only 2 mol of ATP are
generated from anaerobic metabolism of 1 mol of
glucose. Thus an 18-fold increase in glycolytic ﬂux
would be required for compensation of the loss of
aerobic metabolism (Jennings and Reimer, 1981). Since
the entire ATP content of the heart is turned over within
about 5 s, it is not surprising that in the absence of
oxidative phosphorylation neither contractility nor ion
pump activities can be maintained.
In similar experiments with isolated rat hearts reper-
fused for 3 h after a 40 min test ischemia the total
number of cell nuclei, the nuclei of damaged cells, and
the TUNEL-positive nuclei were counted on longitudi-
nal sections with an area of around 80 mm2. The
sections covered almost the entire extension of the left
ventricular free wall and were partitioned by a contin-
uous grid with 40–60 squares (1.44 mm2 each) per
section. An area of 3.9% of each square was counted,
hence 3.9% of the entire left ventricular heart sections
were counted. Total cell nuclei counted per section
ranged from 13,000 up to 26,000. For the assessment of
damaged tissue, the hearts were perfused for the last
15 min with the nuclear stain propidium iodide. Propi-
dium iodide stains only nuclei of damaged cells since it
does not penetrate the cell membrane of viable cells.
After test ischemia without pretreatment, an average of
Fig. 1. Contractility recordings of isolated rat hearts during ischemic
(IPC) and anesthetic (APC) preconditioning, followed by test ischemia
and reperfusion. The hearts (beating at a rate of 280–300 per min) were
perfused over 130 min (20 min served as equilibration period) in the
Langendorﬀ apparatus at constant pressure (80 mmHg) with Krebs–
Henseleit buﬀer gassed with 95% oxygen and 5% carbon dioxide and
glucose. (A) Control heart without treatment; (B) test ischemia of
40 min without prior preconditioning, followed by 30 min of reper-
fusion; (C) IPC protocol with three episodes of 5 min zero-ﬂow
interspersed by short reperfusions, before test ischemia and reperfu-
sion; (D) APC with 15 min 2.1% (vol/vol) isoﬂurane in the perfusate,
followed by test ischemia and reperfusion. LVP, left ventricular
pressure; dp, developed pressure; upper black line, systolic developed
pressure; lower line, diastolic pressure. The shaded area between the
two lines reﬂects the ongoing recovery process during reperfusion after
the test ischemia. IPC signiﬁcantly improves the contractile recovery
compared to the protocol with test ischemia alone. With APC the
contractile performance reaches after 30 min of reperfusion almost
100% of the pre-ischemic value. For further explanations see text.
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66% nuclei stained for propidium iodide, and 2.1%
nuclei were TUNEL-positive. The value for propidium
iodide dropped to 0.2%, while that for TUNEL-
positivity remained at 2.1% in hearts with 15 min
pretreatment by isoﬂurane (2.1% vol/vol). The results
indicate that isoﬂurane fully protects the heart tissue
from cell death under these conditions but leaves the low
percentage of TUNEL-positive nuclei unchanged (un-
published results).
With the isolated heart in vitro it is only possible to
study the early phase of protection. In vivo experiments
or cell cultures are required for testing the delayed
protection phase. However, preconditioning trigger-
dependent transcriptional changes may be detectable
following only 2 h of perfusion in isolated hearts and
may serve as early markers of a delayed cardioprotective
phenotype. Relatively few studies are available that test
the delayed phase with chronically instrumented con-
scious animals (usually rabbit, dog or pig) up to 72 h
after PC (Tissier et al., 2002). The most often employed
protocol, also suitable for small laboratory animals like
mouse or rat, applies IPC or PPC on the ﬁrst day. The
animals are then sacriﬁced 24 h later for testing the
isolated working heart for ischemic susceptibility. Under
certain conditions, however, 24 h may be too short a
period for the development of delayed protection.
Isolated cardiomyocytes in culture
If isolated ventricular myocytes in culture are chosen for
unequivocal identiﬁcation of individual signaling com-
ponents and PC mechanisms, one has to distinguish
between the following preparations: (i) embryonic (usu-
ally chick myocytes), (ii) neonatal (usually chick, rat or
rabbit), and (iii) adult myocytes (usually, rat, rabbit or
pig). For short-term experiments within a period of
12 h, freshly isolated myocytes are seeded and kept in
serum-free medium, where they rapidly attach to the
substratum, preserve their original elongated shape and
remain Ca2+-competent (Jacobson and Piper, 1986). In
the presence of serum, myocytes undergo a drastic de-
and re-diﬀerentiation program with changing surface
receptor population and protein isoform composition
(Eppenberger et al., 1988; Donath et al., 1994). Adult
cardiomyocytes are terminally diﬀerentiated cells that
have lost their ability to divide and represent a higher
level of diﬀerentiaton compared to embryonic, neonatal
or atrial myocytes (Marber, 2000). Freshly isolated
adult ventricular myocytes are preferred for PC experi-
mentation as they more closely reﬂect the response
capacity of the intact adult myocardium. Their disad-
vantage is the low transfection rate with calcium
phosphate as compared to the high degree of transfec-
tion in immature cardiomyocytes. Obtaining consistent
results with myocytes from human atrial appendices has
proven to be diﬃcult. Some work was also done on
atrial myocyte cell lines derived from human atrium
(Girardi cell line) (Carroll and Yellon, 2000) and from
the AT-1 mouse atrial tumour lineage (HL-1 cell line)
(Claycomb et al., 1998). However, these cell lines,
usually cultured in the presence of serum, exhibit a
low diﬀerentiation level and a structural phenotype far
from that of normal cardiomyocytes.
An interesting observation was recently reported for
the isolation and culturing of adult mouse ventricular
myocytes up to 72 h with the percentage of viable, rod-
shaped cells declining from 100 to 60–70% (the original
plating eﬃciency was around 70% rod-shaped myo-
cytes). Mouse myocytes, unlike rat or rabbit myocytes,
are highly susceptible to contracture in culture, which
causes rod-shaped myocytes to become rounded and
lesioned, often ending in death. The long-term myocyte
preservation relies on supplementation of the serum-free
medium at pH 7.0 (instead of the usually adopted pH
7.4) with 10 mM of the contractile inhibitor 2,3-butane-
dione monoxime (BDM) and very low levels of insulin,
transferrin and selenium (O’Connell et al., 2003). Adeno-
virus-mediated expression of an exogenous beta-galact-
osidase reporter gene was maintained by the cultured
myocytes for the entire period of 72 h. This opens the
avenue for studies on signaling for the delayed PC in
cultured myocytes including either vector-based RNA
interference (RNAi) or the expression of dominant
negative signaling proteins.
After application of exogenous PC triggers (anoxia
for 5–20 min in the absence of glucose, or PC inducing
substances and drugs) alone or in combination with
activators or inhibitors of putative signaling compo-
nents, ventricular adult rat cardiomyocytes (VARC) in
serum-free short-term culture may be challenged by a
longer periods (60–180 min) of simulated ischemia (80–
99% nitrogen plus carbon dioxide in the absence of
glucose). Assessment of the portion of dead and viable
cells after the simulated test ischemia serves for end
points such as myocyte contractility, release of the
cytosolic enzymes creatine kinase (CK) or lactate
dehydrogenase (LDH), and nuclear staining with pro-
pidium iodide or trypan blue uptake by lesioned cells
(Marber, 2000).
A more subtle way to follow the cellular response to
PC triggers involves measuring the mitochondrial ﬂavo-
protein ﬂuorescence by time-lapse live cell imaging
microscopy. This represents a functional characterisa-
tion of the PC process and may complement the end
point assessment of cell death after test ischemia.
Mitochondrial autoﬂuorescence is caused by the re-
duced pyridine nucleotides, NAD(P)/H, and by the
oxidised ﬂavoproteins (succinate dehydrogenase, gly-
cerol-3-phosphate dehydrogenase, acyl-CoA dehydro-
genase). These endogenous ﬂuorophores transfer
electrons to oxygen in the inner mitochondrial mem-
brane, ultimately leading to formation of water and
synthesis of ATP. The excitation of ﬂavoproteins is
maximal under full oxidation and minimal under full
reduction, whereas the opposite is true for NAD(P)/H.
The ratio of the concentration of oxidised and reduced
electron carriers or of their ﬂuorescence, respectively,
therefore provides a measure of the cellular metabolic
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state. On the other hand, Marban and his group showed
that the redox state of these endogenous ﬂuorophores
directly reﬂects mitoK-ATP channel activity, and that
opening of this channel is closely associated with
protection against ischemia (Romashko et al., 1998;
Sato et al., 2000).
By the same methodological approach, we recently
demonstrated that volatile anesthetics mediate their
protection in isolated VARC by priming the mitoK-
ATP channels as reﬂected by changes in ﬂavoprotein
ﬂuorescence (Zaugg et al., 2002a, b). Figure 2 shows
that the volatile anesthetic sevoﬂurane (SEVO), which is
known to oﬀer cardioprotection, further enhances the
diazoxide (DIAZO) induced ﬂuorescence level. As
DIAZO is a KCO the results suggest that the cytopro-
tective property of SEVO may, in part at least, depend
on its ability to increase the open probability of the
mitoK-ATP channel. In contrast, R-ketamine (R-KET)
reduced the activity of this channel, which may indicate
that R-KET has an unfavourable eﬀect on the PC
process. Repeated time-lapse sampling allows to record
the drug-induced time-course and amplitude of ﬂuores-
cence changes in many individual myocytes for statis-
tical analysis. In the experiments shown, isoﬂurane with
the isolated heart (Figure 1) and SEVO with the isolated
VARC (Figure 2) were applied in concentrations as
clinically used for anesthesia.
Signaling in the early and delayed cardiac PC
Downey and his group were the ﬁrst to discover that
IPC is receptor-mediated (Liu et al., 1991; Cohen et al.,
2000). In rapid succession, a number of surface recep-
tors capable of inducing PC or contributing to PC was
identiﬁed, all of which belong to the heptahelical
transmembrane G-protein coupled receptor type
(GPCR). The simpliﬁed scheme in Figure 3 summarises
the major signaling pathways for the acute early and the
second delayed IPC phases. Almost all GPCRs present
in cardiomyocytes are capable to induce PC. Beside a
systemic surge of catecholamines under stress, all the
primary messengers for IPC may originate from the
heart tissue and, by local diﬀusion, transmit the stimulus
beyond the ischemic region also to adjacent non-
ischemic tissue (Przyklenk et al., 1993). Transient peri-
ods of rapid heart rate (pacing) or volume overload
(myocyte stretching) can also induce the early phase of
Fig. 2. Eﬀects of the anesthetics SEVO and R-KET on DIAZO-induced ﬂavoprotein oxidation in isolated VARC excited at 480 nm. Emitted
ﬂuorescence was recorded at 530 nm (dark blue indicates reduced, and red indicates fully oxidised ﬂavoproteins). (A) Freshly isolated VARC
immunostained for the M-line protein myomesin and with phalloidin–rhodamine for actin ﬁlaments; (B) ﬂavoprotein ﬂuorescence at baseline; (C)
100 lM DIAZO; (D) SEVO (2.8%, vol/vol); (E) 100 lM DIAZO preceded by SEVO; (F) 100 lM 2,4-dinitrophenol (DNP) for calibration; (G)
ﬂavoprotein ﬂuorescence at baseline; (H) 10 lMR-KET alone; (J) 100 lMDIAZO; (K) 100 lMDIAZO plus 10 lMR-KET; (L) 100 lMDNP.
Note, SEVO and R-KET do not aﬀect baseline ﬂuorescence but SEVO enhances the DIAZO-induced ﬂuorescence level and R-KET reduces it
(results from references Zaugg et al., 2002a, b).
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PC, while a heat shock may promote the delayed PC
phase (Sommerschild and Kirkeboen, 2002). Finally,
short-lasting strenuous bursts of physical exercise with
an up to 15-fold increase of plasma catecholamine levels
(Paterson, 1996), were shown to increase myocardial
ischemic tolerance in experimental animals and in
humans.
In view of the number of primary messengers for PC,
the rather stringent signaling pathway downstream of
the GPCR surprises. It involves activation of phospho-
lipases (PLC, PLD) and liberation of the second
messenger diacyglycerol (DAG) for directly targeting
the PKC (Bolli, 2000; Schulz et al., 2001, 2002; Zaugg
et al., 2003b). PKC represents a key signaling molecule,
which, by phosphorylation, may activate both the
sarcoK-ATP and the mitoK-ATP channels, transcrip-
tion factors including the nuclear factor kB (NF-kB),
and modify other myoﬁbrillar and cytoskeletal proteins
(Schaub et al., 1998; Hahn et al., 2002). Alternatively,
PKC and also the K-ATP channels may be activated
directly by NO (nitric oxide) from intracellular constit-
utively active NO synthase (eNOS) or by NO from
extracellular sources. PKC can also be activated by ROS
arising from mitochondria either during the short
ischemic or the following repetitive reperfusion episodes.
ROS reacting with NO forms peroxynitrite and other
reactive nitrogen oxide species (RNOS), which in turn
also may activate PKC and the mitoK-ATP channel. In
addition, several types of non-receptor tyrosine kinases
(particularly Src and Lck) (not shown in Figure 3) may
be interlinked in the signaling cascades either upstream
and/or downstream of PKC and their targets, the K-
ATP channels. The G-protein subunits Gai and the Gbc
heterodimer were also shown to activate directly the
sarcoK-ATP channels.
In addition to direct signaling for the early protection
phase, PKC also activates several transcription factors,
which lead to the expression of a number of proteins
thought to be involved in promoting the second delayed
protection phase. The late phase is characterised by a
sustained maintenance over several days of similar
primary signals as in the early phase. This is achieved
by an increased expression of proteins ensuring contin-
uous production of NO, and of proteins with antioxi-
dative, cytoprotective and anti-apoptotic potential
(Figure 3). NF-kB was the ﬁrst transcription factor that
was recognised to be essential for the development of the
delayed protection phase. Activated PKC is able to
stimulate NF-kB by phosphorylation of a serine-threo-
nine kinase (IKK), which in turn phosphorylates the
NF-kB inhibitor (IkB), whereupon the latter dissociates
from NF-kB, which can then translocate to the cell
nucleus (Li et al., 2000). Also, in this signaling pathway,
a non-receptor tyrosine kinase (Lck) may be interlinked
Fig. 3. IPC signaling for the early (on the left of the hatched line) and the delayed (on the right of the hatched line) phase of protection. Several
distinct G-protein coupled receptors (GPCR) mediate the primary IPC signals for the early protection by activation of phospholipases (PLC and
PLD), production of DAG, which activates diﬀerent isoforms of PKC. The PKC isoforms further relay the signal to the well-deﬁned ATP-
sensitive membrane potassium (sarcoK-ATP) channels, and to the less well-known mitochondrial K-ATP (mitoK-ATP) channels. In addition to
direct signaling for the early protection phase, PKC also activates transcription factors (including NF-kB), which lead to the expression of a
number of proteins thought to be involved in promoting the delayed protection phase. The delayed phase is characterised by a sustained
maintenance of similar signaling pathways and activation of the sarco- and mitoK-ATP channels similar to the early phase. This is achieved by an
increased expression of proteins ensuring continuous production of NO, antioxidative, cytoprotective, and anti-apoptotic potential. AlRed,
aldose reductase; COX-2, cyclooxygenase type-2; Gai, inhibitory Galpha protein; Gbc, heterodimeric G-protein; HSP, heat shock protein; eNOS,
intracellular constitutively expressed NO synthase; iNOS, inducible NO synthase; IP3, inositoltrisphosphate; IP3R, IP3 receptor; MnSOD,
manganese superoxide dismutase; PIP2, phosphatidylinositol bisphosphate; ROS, reactive oxygen species; RYR, ryanodine Ca2+ release channel;
SERCA2, SR Ca-pump; SR, sarcoplasmic reticulum. Further explanations in the text (for references see: Rubino and Yellon, 2000; Shinmura
et al., 2002; Sommerschild and Kirkeboen, 2002; Zaugg et al., 2003b).
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downstream of PKC. NF-kB is directly involved in
regulation of iNOS, cyclooxygenase type-2 (COX-2) and
aldose reductase (AlRed), which all contribute to
delayed cell protection. iNOS-deﬁcient mice have been
used to show that NO produced by this enzyme is a key
component in the late phase of IPC (Guo et al., 1999).
Additional transcription factors such as the ‘immediate
early genes’ (c-fos, c-myc, Egr-1 and jun-B) and the AP-
1 (heterodimer of c-Fos and c-Jun) become activated
and contribute to gene expression after IPC. Expression
of some of these transcription factors depends on
mitogen activated protein kinase (MAPK) signaling.
Finally, heat shock proteins (HSPs), chaperone proteins
involved in the folding and function of various cellular
proteins, were also shown to be expressed in PC.
Although their role in the delayed PC phase is presently
unclear (Bolli, 2000; Schulz et al., 2001), expression of
HSPs in response to temperature stress and other forms
of stress occurs in species of all 30 eumetazoan phyla
(Feder and Hofmann, 1999).
Similarities in signaling between the early and delayed
phases also concern the steps downstream of PKC. In
both cases PKC signaling is tied in to a positive feedback
loop circling through the mitochondria via the mitoK-
ATP channel that directly stimulates mitochondrial ROS
production (Figure 3). This PC enforcing circuit is
further driven by joining in of NO. In the late PC phase,
NO is steadily produced at a high level by the induction
of iNOS expression over a longer period of time. As a
corollary of the changed gene expression proﬁle in
delayed cardioprotection, the early and the late phase are
expected to diﬀer from one another not only in time and
degree of protection. IPC reduces infarct size more in the
early than the late phase. On the other hand, myocardial
stunning is more mitigated in the late than the early
phase (Bolli, 2000). The duration of the short early phase
can be extended neither by continuous infusion of
pharmacological triggers nor by repeated brief ischemic
episodes, while administration of an adenosine receptor
agonist at 48 h intervals resulted in the maintenance of
continuous protection against infarction in a rabbit
model for at least 10 days without evidence of downre-
gulation of receptor function (Dana et al., 1998). How-
ever, the cellular mechanisms involved in early and
delayed PC are likely to show some variation depending
on type and degree of the induction stimulus.
Memory, redundancy, and speciﬁcity in PC signaling
In the context of early and delayed PC, four aspects
have emerged as particularly interesting in PC research:
(i) the memory state of the preconditioned myocyte; (ii)
the redundancy in the primary IPC signaling; (iii) signal
speciﬁcities for PC; and (iv) the role of the mitoK-ATP
channel in PC as trigger, mediator, or end eﬀector.
(i) A characteristic feature of PC is the ‘memory’
phenomenon. The cell ‘remembers’ that it has been
exposed to ischemic stress, hence, the initial stimulus
induced alterations in the cell, which can last over a
certain time period, either for 1–3 h or from 24 up to
72 h. Diﬀerent mechanisms must be responsible for the
short- and the long-term memory, but in both cases
signiﬁcant changes in the intracellular homeostasis must
have occurred. The mechanisms for the long-term
memory may be intuitively easier to apprehend. The
ischemia-reperfusion stress the myocyte was exposed to,
was suﬃciently severe so that the increased cytosolic
Ca2+, the primary messengers, and ROS were able to
alter gene expression (Figure 3). From the rabbit model,
where continuous protection resulted from repeated
administration of an adenosine agonist (Dana et al.,
1998), it may be inferred that the release of primary
messengers, suﬃcient for maintaining the PC gene
expression program, persists for 3–4 days provided the
original IPC stimulus was strong enough.
For the short-term memory over 1–3 h, de novo
protein synthesis seems not to be required, although
some of the immediate early genes may already be
activated during this phase. Most of these early genes
are transcription factors, which activate further genes
encoding proteins needed later in the process. The short-
term memory appears to depend on trigger-induced
activation of an ensemble of protein kinases and
phosphatases including PKC. Depending on the phos-
phorylation state, protein kinases may translocate to
particular subcellular compartments such as sarcolem-
ma, mitochondria, intercalated discs or nuclei, where
they are poised near their targets should the need arise
for quick activation (Cohen et al., 2000; Newton, 2003).
However, the data supporting the translocation hypoth-
esis are controversial. Few studies have shown a
correlation of PKC translocation with the presence of
a protected state (Kawamura et al., 1998).
(ii) The majority of hormones, neurotransmitters, and
vasoactive peptides, which are able to induce PC exert
their eﬀects through GPCRs (Figure 3). Therefore,
considerable redundancy exists among the primary
endogenous messengers (Cohen et al., 2000; Schulz
et al., 2001). About as many GPCR subtypes as there
are primary messengers, are responsible for transmission
of their signal to the cell interior (Figure 4). The
redundancy was shown in the rabbit heart model with
the main three endogenous PC triggers, adenosine,
bradykinin and opioids. In the rabbit, a single brief
ischemic event suﬃces to induce PC. Blocking any of the
three respective receptors completely abolished PC,
suggesting that the threshold for PC induction was no
more reached. However, blocking of the bradykinin B2
receptor with HOE140 did not abrogate PC after four
brief repetitive ischemic episodes. Thus a stronger IPC
stimulus led to suﬃcient release of adenosine, opioids
and other triggers to overcome the blockade of the B2
receptor. These results indicate that contributions to PC
by the individual triggers are additive, but their relative
importance may vary according to the type of stress
stimulus and species.
From the GPCRs the signals are transferred to four
types of G-proteins with diﬀerent speciﬁcities for en-
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zymes, which in turn, produce the second messengers.
These speciﬁcally activate distinct serine-threonine pro-
tein kinases (PKA, PKC and PKG). At this stage,
several signals known to induce PC, are channelled via
PKC to their targets at the surface membrane and at the
mitochondria (Figure 4). Within the Gi-protein family,
the signaling ﬂows equally through both the Gai and the
Gbc complex, which latter may directly aﬀect the
sarcoK-ATP channel in the sarcolemma (Neves et al.,
2002; Rockman et al., 2002). It was recently shown that
the brain (or ventricular) natriuretic peptide (BNP) is
also able to induce PC in isolated rat hearts by elevation
of the second messenger cGMP (D’Souza et al., 2003).
BNP binds to the natriuretic peptide receptor type-A, a
membrane-bound particulate guanylyl cyclase, diﬀerent
from the GPCR family.
In view of the extensive cross-connections between the
diﬀerent signaling pathways, it cannot be expected that
the signaling for PC is very speciﬁc. The redundancy
among the primary messengers continues along the
downstream signaling pathways. In fact, the signaling
for PC activates at the same time, a multitude of
signaling pathways and, consequently, aﬀects also a
multitude of cellular properties including contractility,
metabolism, and gene expression.
(iii) Nevertheless, some speciﬁcity in signaling for the
eﬀects characteristic for PC must be secured. It seems
that PKC is the key player in the coordinated signal
transfer to the appropriate sites of action. The PKC
exists in a variety of isoforms with functional speciﬁ-
cities. There are 10 mammalian PKC isoforms. The four
conventional PKCs (a, b1, and a splice variant b2, and
c) require Ca2+ and diacylglycerol (DAG) for activa-
tion; the four novel PKCs (d, e, g/L and h) are Ca2+-
independent but require DAG for activation; ﬁnally, the
two atypical PKCs (f and k) lack both the Ca2+ and the
DAG binding domains (Newton, 2003). In the inactive
conformation in the cytosol, PKC binds a pseudosub-
strate sequence to the substrate-binding cavity. Gener-
ation of DAG (and Ca2+) recruits PKC to the
membrane. The membrane binding provides the energy
to release the pseudosubstrate sequence from the active
site, allowing substrate binding and phosphorylation for
full activity. Which PKC isoform may be the major one
for inducing PC, or which isoform is targeted to which
membrane sites was shown to depend on the animal
Fig. 4. Surface receptor signaling system for PC. Most PC signals from the extracellular primary messengers are transmitted to the intracellular
secondary messengers by the G-protein coupled receptors. Further downstream signaling is mediated by target speciﬁc serine-threonine kinases
(PKA, PKB, PKC, PKG). Note the intimate cross-talk between the individual signaling pathways. Lines with blunted end (=) indicates
inhibition. A1, A3, adenosine receptors; AC, adenylyl cyclase; ACh, acetylcholine; ANP, BNP, atrial and brain natriuretic peptide; AR,
adrenergic receptor; AT1, angiotensin-II receptor; DAG, diacylglycerol; ET1, endothelin receptor; GC, cytosolic soluble guanylyl cyclase;GC-A,
membrane receptor for ANP with integrated guanylyl cyclase; Gi, Gs, Gq, G-protein subunits; IP3, inositoltrisphosphate; M2, muscarinic
acetylcholine receptor; NOS, NO synthase; NPR-A, natriuretic peptide receptor type-A; PDK1, phosphoinositide-dependent kinase-1; PI3K,
phosphoinositide-3 kinase; PLC, phospholipase-C; RNOS, reactive nitric oxide species. Further explanations in the text (for references see:
Brodde et al., 2001; Rockman et al., 2002; Zaugg et al., 2002c; Neves and Iyengar, 2002; D’Souza et al., 2003; Newton, 2003).
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model and stress stimuli (Pepe, 2001; Schulz et al.,
2001). PKCe seems most important for PC in rabbits,
PKCd in rats, and PKCa in dogs. On translocation to
membranes, PKCe interacts with an anchoring protein
called RACK2 (receptor for activated C-kinase). In fact,
each PKC isoform may bind only to its speciﬁc RACK
protein (Mackay and Mochly-Rosen, 2001). When
recruited to the mitochondria, PKCe was shown in
mouse myocytes to associate with several other proteins
as well, including the voltage-dependent anion channel
(VDAC), the adenine nucleotide translocator (ANT)
(for characterisation of VDAC and ANT see Section
‘what makes up the mitochondrial permeability transi-
tion pore?’), hexokinase-II, and with mitogen activated
protein kinases (MAPK) (Baines et al., 2002, 2003).
After IPC and anesthetic PC with isoﬂurane, we
observed in rat hearts that PKCd translocated to
mitochondria but not to the sarcolemma, and PKCe
translocated to the sarcolemma and intercalated
discs but not to mitochondria (Uecker et al., 2003).
Signal speciﬁcity in IPC and PPC is thus achieved
by speciﬁc interactions of distinct PKC isoforms with
other structural or functional components forming a
signaling module at the site of action and not by
individual signaling pathways attributable to a particu-
lar function.
(iv) To address the questions, as to which role the
mitoK-ATP channel plays in PC, and whether it acts as
trigger, mediator, or end eﬀector, a look into its protein
structure and function is required ﬁrst. Furthermore, the
contribution of the mitochondria to the cellular mech-
anisms of PC and their relation to this channel warrants
some detailed consideration. This is done in the Sections
‘Key players in ischemic and pharmacological PC’ and
‘ATP-sensitive potassium channels’. The question about
the signiﬁcance of the mitoK-ATP channel in PC is
discussed in Section ‘Is the mitochondrial K-ATP
channel playing the main role in PC?’.
Signaling ampliﬁcation cascades
Figure 4 indicates the primary signaling for PC down to
the level of the serine-threonine protein kinases. Among
the latter, the PKC isoforms are most prominent and
provide speciﬁcity for distinct subcellular eﬀects in-
volved in PC. This primary signaling needs to be seen in
context with the major signaling cascades of the mitogen
activated protein kinases (MAPK) and the stress acti-
vated JAK-STAT pathway as well (Figure 5). The
MAPK cascades represent a characteristic phosphorelay
system, in which a series of three protein kinases
phosphorylate and activate one another (Johnson and
Lapadat, 2002). The extracellular signal regulated kin-
ases (ERK pathway) function in the control of cell
division; the c-Jun N-terminal kinases (JNK pathway)
are critical regulators of transcription; and the p38
MAPKs (p38 pathway) are activated by inﬂammatory
cytokines and environmental stresses, and may contri-
bute to diseases like asthma and autoimmunity.
The interconnections between the diﬀerent signaling
pathways given in Figure 5 represent only those report-
ed, but probably many more exist in reality (Hefti et al.,
1997; Bolli et al., 1001; Molkentin and Dorn, 2001). Co-
activation of diﬀerent pathways, may thus be expected.
In fact, the involvement of all three MAPK cascades as
well as the JAK-STAT pathway in PC was reported
(Bolli et al., 2001; Heidkamp et al., 2001; Xuan et al.,
2001; Baines et al., 2002; Steenbergen, 2002; Da Silva
et al., 2003). The JAK-STAT pathway is now recogn-
ised as an important membrane-to-nucleus signaling
relay for a variety of stress responses including ischemia
and oxidative stress. Angiotensin-II-induced PC in-
volves the JAK-STAT pathway (Hattori et al., 2001).
Erythropoietin is a paracrine mediator of ischemic
tolerance and was recently shown to signal via its
cytokine receptor to JAK and the anti-apoptotic signal-
ing pathway involving the phosphoinositide-3 kinase
(PI3K), phosphoinositide-dependent kinase-1 (PDK1)
and protein kinase-B (PKB) (Ruscher et al., 2002;
Calvillo et al., 2003). Growth factors such as insulin-
like growth factor-1 (IGF-I) or epidermal growth factor
(EGF) as well as some cytokines stimulate the expres-
sion of cytoprotective mediators, which indirectly im-
prove the recovery from oxidative stress. Big MAP
kinase-1 (BMK1), also known as ERK5, is a newly
identiﬁed member of the the MAPK family and is
reported to be sensitive to oxidative stress. On PC12
cells (pheochromocytoma cells) it was shown that
BMK1 activated by hydrogen peroxide counteracts
ischemic cell damage probably by activation of the
transcription factor MEF2C (Suzaki et al., 2002).
The pattern and degree of activation of distinct
signaling pathways seems complex, but it may depend
on the type and intensity of the stimulus, time of
sampling of the tissue (before, during or after the test
ischemia), and on the species examined. It appears that
most eﬀects stimulated by the MAPK cascades and the
cytokine type of receptors, act via modiﬁcation of gene
expression and may therefore, be more important for
late cardioprotection.
Key players in ischemic and pharmacological PC
Mitochondria as target for cytotoxicity and
cytoprotection
The myocardium, as a continuously working pump,
depends on an eﬃcient and continuous energy produc-
tion. The heart constitutes less than 0.5% of the body
mass, yet it consumes around 11% of the total energy
required for living. By complete oxidation of glucose to
carbon dioxide and water, the mitochondria are able to
extract about 12 times more energy than by anaerobic
metabolism in the cytosol. Of the total ATP production,
60–70% is used for the contractile apparatus and 10–
25% for ion movements (Ca- and Na/K-pumps).
However, a great part of the energy from ATP dissipates
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into heat and only around 20–25% are converted into
external mechanical work (Opie, 1997).
Cardiomyocytes have the highest mitochondrial con-
tent with a volume fraction inversely proportional to
body size varying from 22% in pigs up to 38% in mice
(Canale et al., 1986). As the energy consuming mecha-
nical function of the myocyte depends on a continuous
energy production by the mitochondria, the two require
a tight coupling and coordinated regulation. The myo-
cyte and the mitochondria represent two compartments
with diﬀerent and highly specialised functions like a
small cell encased by a bigger one (Figure 6). In fact,
this situation reﬂects its evolutionary history, according
to which the eukaryotic cells started without mitochon-
dria. More than a billion years ago, when oxygen in
substantial amounts entered the atmosphere, the eukar-
yotic cells established a stable endosymbiotic relation
with a bacterium, whose oxidative phosphorylation
system they subverted for their own use (Sogin, 1997).
The mutual integration in the eukaryotic cells is secured
in two ways: (i) the most prominent second messenger,
namely Ca2+, acts as a major communicator between
the cytosolic and the mitochondrial matrix (MM)
compartments (Carafoli, 2002), and (ii) a continuous
metabolic relay system links the cell surface electrical
events directly to the energy production centre in the
mitochondria (Dzeja and Terzic, 2003). This is achieved
through a coupled near-equilibrium enzymatic network
involving several shuttle systems. ATP delivery is
facilitated by creatine kinase (CK) adenylate kinase
Fig. 5. Relation between PKC signaling for preconditioning (PC) and the major signaling cascades of the MAPK and the JAK-STAT pathways.
The heavy arrows follow the main signaling pathways operative in both ischemic (IPC) and pharmacological (PPC) preconditioning. Both IPC
and PPC may also activate the MAPK cascades. The MAPKs are part of a phosphorelay system composed of three sequentially activated kinases
(MKKK–MKK–MAPK), and, like their substrates, MAPKs are regulated by phosphorylation. Note the intimate cross-connections between the
GPCR signaling and the MAPK cascades. Some growth factors and cytokines are also able to induce PC. Open arrows indicate cytosolic eﬀects.
Dashed arrow indicates hypothetical direct mechanical signaling to the nucleus. Cdc42, Rac, Ras, small monomeric GTPases; CR, cytokine
receptor; DAG, diacylglycerol; EGF, epidermal growth factor; ERK, extracellular signal regulated kinase; Gi, Gs, Gq, Gbc, diﬀerent G-protein
subunits; IGF-I, insulin-like growth factor-1; IP3, inositol trisphosphate; JAK, Janus kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen
activated protein kinase; MEK, mitogen activated ERK activating kinase; MEKK, MEK kinase; MKK, MAPK kinase; MKKK, MAPKK
kinase; p38, p38 MAP kinase; PDK1, phosphoinositide-dependent kinase-1; PI3K, phosphoinositide-3 kinase; PIP2, phosphatidylinositol
bisphosphate; PKA, PKB, PKC, speciﬁc serine-threonine kinases; PLC, phospholipase-C; Ras, Rac, Cdc42, monomeric small GTPases; RTK,
receptor tyrosine kinase; STAT, signal transducer and activator of transcription. Further explanations in the text (for references see Hefti et al.,
1997; Bolli et al., 2001; Michel et al., 2001; Molkentin and Dorn, 2001; Baines et al., 2002; Calvillo et al., 2003).
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(AK), and the glycolytic system comprising hexokinase,
pyruvate kinase, and phosphoglycerate kinase (PGK).
ADP is removed by the CK, AK, and PGK shuttles. As
these shuttle systems work in parallel, a diminished
activity of a single enzyme may well be tolerated. Only
malfunction of several enzymes together will severely
compromise the communication between ATP-generat-
ing and ATP-consuming sites. Thus, the mitochondria
are at the cell’s crossroad of life and death. Below, the
contribution of the mitochondria to the cellular mech-
anisms involved in ischemia-reperfusion injury and in
potential protective interventions will be discussed.
Mitochondrial calcium, friend or foe?
The cytosolic Ca2+ levels ﬂuctuate between 10)8 and
10)6 M. The fast Ca2+ transients for contraction are
mainly governed by Ca2+ release from the SR via the
ryanodine Ca2+ release channel (RYR), and reuptake
by the SR Ca-pump (SERCA2) (Figure 3). Ca2+ from
outside enters the myocyte through the L-type Ca-
channel, the so-called dihydropyridine receptor
(DHPR), and the sarcolemmal Na/Ca-exchanger ex-
trudes Ca2+ from the cell in exchange for Na+ uptake.
During the action potential plateau, Ca2+ extrusion is
inhibited and the exchanger may uptake Ca2+ by
working in the reverse mode. Ca2+ in the MM tends
to follow cytosolic Ca2+ levels, being taken up via the
Ca-uniporter and released through the mitochondrial
Na/Ca-exchanger. The Ca-uniporter is sensitive to
ruthenium red and is highly dependent on the mito-
chondrial inner membrane potential (DYm). The Na/Ca-
exchanger can be inhibited by diltiazem (a benzothiaze-
pine and Ca-channel blocker) and clonazepam (a
benzodiazepine). Both the sarcolemmal and the mito-
chondrial exchanger move 3Na+ ions against 1Ca2+ ion
(Suleiman et al., 2001). Fast Ca2+ exchange of the MM
with its surroundings is facilitated by the close structural
proximity of mitochondria to the SR membranes from
where Ca2+ may be released (Rizzuto et al., 1998). In
the MM Ca2+ stimulates the mitochondrial metabolism
by regulating three key enzymes (pyruvate-, isocitrate-
and oxoglutarate-dehydrogenases) of the TCAC (Joua-
ville et al., 1999). This is paralleled by a rapid increase in
NADH levels, feeding protons into the respiratory chain
at the inner mitochondrial membrane (IMM) for ATP
production. Any increase in cytosolic Ca2+ entails a
corresponding Ca2+ increase in the MM (Figure 6). As
long as these Ca2+ ﬂuctuations remain within the
physiological limits, it seems reasonable that higher
myocyte activity calls for an increase in oxidative energy
production by stimulating the TCAC. While the human
heart pumps 6–8 l of blood per min at rest, this may
increase up to 8-fold during physical exercise. The
relation between energy demands and MM Ca2+ is
given by the scheme:
Increased workload and/or hormonal stimulation
! energy demand "!cytosolic Ca2þ "
!mitochondrial Ca2þ "!dehydrogenase activities "
!NADH "!ATP "!energy supply "
Mitochondrial Ca2+ overload occurs, however, when
mitochondria are exposed to maintained Ca2+ levels
(not transients) exceeding 1–2 lM. When cardiomyo-
cytes loaded with the ﬂuorescent Ca2+ indicator aequo-
Fig. 6. Hypothetical mechanisms of cardiomyocyte ischemia-reperfu-
sion injury and its potential prevention. Ca, sarcolemmal L-type Ca-
channel; K, sarco- and mitoK-ATP channels; PTP, mitochondrial
permeability transition pore; ROS, reactive oxygen species. (±) stands
for voltage element. (A) Under normal conditions with high ATP/ADP
ratio the K-ATP channels are closed and mitochondrial matrix (MM)
Ca2+ is in equilibrium with cytosolic Ca2+. (B) Lack of oxygen
prevents ATP production, causing a decrease in diﬀusive K+ inﬂux.
The MM volume shrinks on the expense of the intermembrane space,
which expands. The low ATP/ADP ratio in the cytosol enhances the
open probability of the sarcoK-ATP channel, while the mitoK-ATP
channel remains closed in presence of ADP. Consequently, both
cytosol and MM become Ca2+ overloaded, and as soon as reperfusion
starts the PTP opens inducing massive mitochondrial swelling, outer
membrane disruption and cell death. (C) Opening of the mitoK-ATP
channel by IPC or PPC (e.g. with K-ATP channel openers) regulates
volume of MM by moderate swelling, this allows ATP production to
restart at reoxygenation, the mitochondrial inner membrane potential
can be restored and the PTP remains closed. At the same time,
shortening of the action potential duration decreases the cytosolic
Ca2+ overload. Further explanations in the text (for references see
Crompton et al., 2002; Dos Santos et al., 2002; Halestrap et al., 2002;
Zaugg et al., 2003b).
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rin (a 21,000 Da protein originally extracted from the
jellyﬁsh Aequorea forskalea) are subjected to anoxia, a
progressive rise in resting cytosolic Ca2+ is observed
(Crompton et al., 2002). This increased cytosolic Ca2+
reverses on reoxygenation provided the limit of 1–3 lM
Ca2+ is not exceeded. If it is exceeded the myocytes
undergo irreversible lethal injury. The combination of
high MM Ca2+ levels, together with high inorganic
phosphate (Pi), oxidative stress, and low extramito-
chondrial ATP unequivocally leads to the so-called
mitochondrial permeability transition. This process
involves opening of the mitochondrial permeability
transition pore (mitoPTP), a non-speciﬁc pore, per-
meant to any molecule smaller than 1500 Da, that opens
in the IMM. As a consequence of inﬂux of solutes and
water from the cytosol, the open pore induces massive
swelling of the mitochondria, which can be accomodat-
ed by the extensively folded IMM, but not by the tightly
ﬁtting outer mitochondrial membrane (OMM). Conse-
quently, the OMM becomes disrupted, which is fol-
lowed by release of components from the mitochondrial
intermembrane space (MIMS) that trigger apoptosis
and/or necrosis. In addition, mitochondria become
depolarised, causing inhibition of oxidative phosphory-
lation and stimulation of ATP hydrolysis, in particular
by the diﬀerent phosphorelay systems working near
equilibrium. Even the mitochondrial ATP synthase may
hydrolyse ATP by working in the reverse mode under
these conditions.
What makes up the mitochondrial permeability transition
pore?
The Ca2+ induced mitochondrial permeability transition
was ﬁrst described in 1979 (Hunter and Haworth, 1979;
Haworth and Hunter, 1979). But the structure of the
mitoPTP is still debated. Halestrap and his group
present a model, in which the adenine nucleotide
translocator (ANT) spans the MIMS from the IMM
to the OMM, thus facing on the inner side the MM
where under normal conditions ATP is bound, and on
the outer side the cytosol, where ADP is bound
(Halestrap et al., 2002). The nucleotides stabilise its
structure. The MgATP complex does not bind to the
ANT. Binding of Ca2+ to an intramitochondrial loop of
the ANT triggers a conformational change required for
pore formation, which is, however, antagonised by
Mg2+ and other divalent cations. The closed pore is
called the m-state and the open pore the c-state. The
transition from the closed m- to the open c-state is
brought about by the mitochondrial cyclophilin-D
(CyPD), a peptidyl-prolyl cis–trans isomerase in the
MM. Cyclosporin-A (CsA) and its analogues inhibit
CyPD and thus inhibit pore formation. Under energised
conditions (but not de-energised conditions) atractylo-
side, and more speciﬁc carboxyatractyloside (CAT),
favours pore formation while bongkrekic acid and
triﬂuoperazine stabilise the closed form. A pH below 7
is a potent inhibitor of pore formation, probably
resulting from protons competing with Ca2+ for its
binding at the trigger site. This model of Halestrap
comprises the minimum conﬁguration of the mitoPTP
requiring no other outer membrane protein. However,
MIMS proteins including Bcl2, Bax, and others may
interact with the ANT to regulate the mitoPTP.
Crompton an his coworkers believe the IMM and
OMM are held together by junctional complexes of the
ANT at the inner and the voltage-dependent anion
channel (VDAC or porin) at the outer membrane
(Crompton et al., 2002). Under normal condition the
VDAC is permeable to solutes up to about 5000 Da
(Kroemer and Reed, 2000). Thus, whereas the MM
contains a highly selective set of small molecules, the
MIMS is chemically equivalent to the cytosol with
respect to low molecular weight solutes. Three isoforms
of both the VDAC and the ANT have been recognised.
These junctional complexes may act as dynamic recruit-
ment centres, binding a range of proteins according to
functional needs. Some of the additional constituents
involve protein kinases, enzymes of lipid transfer, and
others. It was also proposed that the peripheral benzo-
diazepine receptor might be an integral component of
the mitoPTP (Zoratti and Szabo, 1994). Physical disrup-
tion of the functioning complex facilitates the pore
opening, which may be considered to represent a
pathological process. The complex of ANT–VDAC
together with CyPD reconstitutes Ca2+- and CsA-sensi-
tive mitoPTP activity when incorporated into proteo-
liposomes (Crompton et al., 2002). This tertiary complex
is considered to represent a physiological entity in the
mitochondria of healthy cardiomyocytes. Two speciﬁc
functions need mentioning. First, the tertiary complex
seems to take part in intermitochondrial junctions,
providing ionic continuity between the matrix spaces of
the conjugated mitochondria, and allowing the proton
electrochemical gradient to be conducted from one
mitochondrion to the next. In cardiomyocytes, conju-
gated mitochondria form intermyoﬁbrillar networks for
the eﬃcient distribution of the proton motive force
throughout the cell (Skulachev, 2001). Second, the outer
protein VDAC is also able to recruit hexokinase and
glycerol kinase from the cytosol in order to bring sites of
ATP usage in the cytosol close to the sites of mito-
chondrial ATP export. These observations would point
to a functional coordination in nucleotide transloca-
tion between the VDAC and the ANT. These two proteins
are the most abundant in the mitochondrial membranes.
But yet another protein seems to be involved in
mediating translocation of energy phosphoryls between
the inner and outer mitochondrial membranes. As ADP
is poorly diﬀusible in the cytoplasm, mitochondria need
to work in tandem with a cytosolic shuttle system for
eﬃcient distribution of ATP energy throughout the
myocyte. Wallimann and his group propose a still more
sophisticated mitochondrial contact site between IMM
and OMM by placing the mitochondrial creatine kinase
isoform (mitoCK) between the ANT and the VDAC
(Dolder et al., 2001, and references therein). MitoCK
233
forms an octameric cube structure with a hollow pore in
its centre. Physical contact of octameric mitoCK with
the VDAC is Ca2+-dependent and can be experimentally
demonstrated in vitro, while physical contact with the
ANT remains elusive (Schlattner et al., 2001). However,
it was shown that the proper mitoCK octamer in the
ternary complex with the ANT and the VDAC, is able
to regulate functionally the transition of the ANT
between the open c-state and the closed m-state. If
CyPD is present as well, the quarternary complex
regains its CsA-sensitivity.
Together with the ANT of the IMM and the VDAC
of the OMM, mitoCK may form a functional micro-
compartment in the MIMS. ATP produced by oxidative
phosphorylation in the MM is exported by the ANT,
and channelled to the active site of mitoCK for
transphosphorylation to CrP. CrP that is well diﬀusible
is then funnelled to the VDAC to be expelled to the
cytosol, while ADP is channelled back to the mito-
chondrial MM via the ANT to further support oxidative
phosphorylation. In view of the limited permeability of
the OMM for adenine nucleotides, this model assures
that the ATP and ADP pools in the cytosol and MIMS
remain separated and do not intermix. Furthermore,
mitoCK in this position exerts a major control over
oxidative phosphorylation. Factors impairing the acti-
vity and/or destabilising the octameric structure of
mitoCK were shown to destabilise the cohesion of the
junctional protein complex and to increase the mitoPTP
open probability (Dolder et al., 2003). Dimeric or
monomeric mitoCK does not stabilise the ANT as does
the octameric structure. MitoCK is particularly sensitive
to reaction with ROS, which modify its active site
Cys278. This represents a well deﬁned pathway for ROS
cytotoxicity during reperfusion injury. It helps under-
standing the apparent paradox that the most serious
damage does not occur during the anoxic phase, but
after reoxygenation.
Does opening of the mitoPTP irrevocably lead to cell
death?
The complex of several proteins, each with speciﬁc
translocator and/or enzymatic properties, is required for
the physiologically meaningful translocation of energy
phosphoryls from the MM to the cytosol. Physical
disruption of the functioning complex facilitates the
pore opening, which may be considered as a patholo-
gical process.
Whether the open pore is formed by the ANT alone or
in conjunction with the VDAC is not clear at present.
The pro-apoptotic components Bax, atractyloside, Ca2+,
palmitate, and thiol oxidants, induce the open pore state
of the ANT. However, in vitro experiments have shown
that the VDAC can assume an open state large enough
for cytochrome-c with a molecular weight of 12,000 Da
to pass through. This open state is enhanced by Bax and
inhibited by the anti-apoptotic Bcl2. Thus it seems
feasible that the VDAC may open and close indepen-
dently of the ANT, releasing cytochrome-c, apoptosis-
inducing factor (AIF), certain pro-caspases, Smac/
DIABLO, and endonuclease-G from the MIMS to the
cytosol (Kroemer and Reed, 2000). Both Bax and Bcl2
are primarily found in the OMM, however, they are also
involved in regulation of the ANT component. Fur-
thermore, Bax can oligomerise and form an autonomous
protein translocating channel in the OMM, the activity
of which may be enhanced by Bid, independently of the
VDAC. Nonetheless, the open mitoPTP controls the
permability of both the inner and outer mitochondrial
membranes. At the contact sites, changes in the confor-
mation of the ANT, modulated by its interaction with
CyPD, may directly impinge on the function of the
VDAC, and vice versa.
The IMM potential DYm results from the electron
transport chain, pumping protons out of the MM, and is
indispensable for driving the ATP synthase, which
phosphorylates ADP to ATP. ATP generated on the
matrix side of the IMM is then exported in exchange for
ADP by the ANT. Upon extensive pore opening, the
DYm collapses and ATP dissipates, which is accompa-
nied by a rapid loss of cell viability. Rupture of the
OMM releases cytochrome-c, and triggers the caspase
cascade.
The permeability transition of any individual mito-
chondrion is thought to be an all or none phenomenon.
When widespread irreversible mitoPTP opening occurs
throughout a cell’s mitochondria, cell death is inevita-
ble. However, within a population, individual mito-
chondria may possess diﬀerent sensitivities to openers of
the mitoPTP. In fact, by entrapping Ca2+ buﬀers in the
MM space in the presence of Ca2+ transport inhibitors,
it could be shown in isolated mitochondria that the
mitoPTP open and close continuously at a frequency
that is determined by the matrix Ca2+ level. No critical
Ca2+ threshold was apparent, and the relation between
pore opening and matrix Ca2+ remains linear up to
20 lM Ca2+ (Crompton et al., 2002). Thus a limited
degree of pore opening may be tolerated by the cell. The
energy transduction would be less eﬃcient, but this
would not constitute an immediate threat to cellular
survival, provided a suﬃcient minimal ATP level can be
maintained. At any matrix Ca2+ level, there is a
dynamic steady state between mitochondria with open
pores and those with closed pores. At low MM Ca2+
loads, when only a small fraction of mitochondria have
open pores at any given time, the DYm is maintained by
the remainder. It was further shown, that transient pore
opening is suﬃcient to release cytochrome-c (Gogvadze
et al., 2001). Whether transient mitoPTP opening with
concomitant cytochrome-c release occurs in vivo is not
known. What could be the physiological meaning of a
low level pore activity with concomitant release of small
amounts of cytochrome-c? The pore open probability
may be coupled to the IMM DYm, and the cytochrome-
c may, by activating catabolic enzymes in the cytosol,
contribute to the turnover of cell constituents. As the
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ﬂuctuating pore activity depends on the Ca2+ level, one
may speculate that it represents yet another intracellular
Ca2+ regulated control device.
Cellular cytotoxic mechanisms
While the phosphoryl translocation between MM and
cytosol represents the physiological function of the
mitoPTP protein complex, its conversion to the patho-
logical open state can lead to cell death. Why is
sustained pore opening lethal for the cell? It produces
two major detrimental eﬀects: (i) swelling of the MM
until physical disruption of the OMM occurs, inducing
cell death signaling pathways, and (ii) collapse of the
DYm, which interrupts energy production. Further-
more, pore opening is mainly occurring upon reoxygen-
ation during reperfusion, when the cytosol and the MM
are Ca2+ overloaded and cytotoxic concentrations of
ROS are generated.
ROS are generated as byproducts of the cellular
metabolism, primarily by xanthine oxidase and by the
mitochondrial respiratory chain. Thus mitochondria
serve both as producers and as targets of ROS. ROS
function as subcellular messengers, play a role in gene
regulation, and are involved in defensive mechanisms
against oxidative stress (for review see Droge, 2002).
The superoxide radical (O2 ) and consequently hydrogen
peroxide (H2O2) (as a product of the mitochondrial
superoxide dismutase, Mn-SOD) originate primarily
from complex-I and complex-III of the respiratory
chain. Excess and/or sustained ROS production exceed-
ing the antioxidant capacity, leads to damage of
membrane lipids, proteins, and DNA. ROS have direct
eﬀects on several components of the respiratory chain,
the ATP synthase and the ANT, probably by modiﬁca-
tion of protein thiol groups (Suleiman et al., 2001). ROS
can also damage sarcolemmal membrane ion pumps
and, therefore, exacerbate the eﬀects of ATP deprivation
on cell ion dysregulation. NO was also proposed to
induce mitochondrial dysfunction. NO can reversibly
inhibit cytochrome oxidase and thus aﬀect mitochond-
rial respiration; but its more permanent damage may
occur through NO-enhanced production of mitochond-
rial ROS upon reperfusion.
Recognising the steps occurring in sequence during
reperfusion injury, allows to develop strategies to stop
the process at diﬀerent points. The schematic drawings
in Figure 6 visualise the intracellular relations between
the activities of the sarco- and mitoK-ATP channels, the
sarcolemmal L-type Ca-channel, the mitoPTP, and their
eﬀects on the sarcolemmal and mitochondrial mem-
brane potentials and Ca2+ homeostasis.
First, under normal conditions, the K-ATP channels
and the mitoPTP are virtually closed, and Ca2+ equili-
brates between the cytosol and the MM (Figure 6A).
Second, the scheme in Figure 6B depicts the situation at
the end of the ischemic period, at the moment when
reperfusion would start. Due to the lack of oxygen
during ischemia, the DYm depolarises somewhat, caus-
ing a decrease in diﬀusive K+ inﬂux. As K+ in the MM is
the main volume regulator, the matrix volume contracts
by 10–20% until the K/H-antiporter brings inﬂux and
eﬄux into balance, at which time the matrix volume
achieves a new steady state at lower levels (Dos Santos
et al., 2002; Halestrap et al., 2002). The concomitant
expansion of the MIMS destabilises the mitoPTP
complex, thereby impairing the transfer of cytosolic
ADP to the MM in exchange of ATP. The instability of
the mitoPTP renders the VDAC permable for the
nucleotides, which then equilibrate across the OMM.
As a corollary, the ATP synthesis comes to an almost
complete halt and ATP is rapidly degraded to ADP and
AMP. The deﬁcient energy supply to the cell periphery
inhibits the sarcolemmal Na/K-pump, which entails a
decrease of intracellular K+ and an increase of Na+ and
Ca2+. This shift of intracellular ion levels causes a
reduction of the resting potential. The action potential
duration (APD) increases because of the delayed repo-
larisation, and due to both, the reduced resting potential
and the prolonged APD, the cytosol becomes further
overloaded with Ca2+ that overﬂows into the MM
(Figure 6B). The increased ADP in the cytosol mode-
rately stimulates the sarcoK-ATP channels, while the
mitoK-ATP channels still remain closed by the in-
creased ADP in the MM (Dos Santos et al., 2002).
However, this limited activation of the sarcoK-ATP
channels is able to revert neither the decrease of the
resting potential nor the prolongation of the APD. If
reperfusion starts after a period of prolonged ischemia
at the point shown in Figure 6B, the mitoPTP opens
with its fatal consequences for the cell: production
of ROS, collapse of the DYm, massive mitochondrial
swelling and OMM rupture. When the permeability
barrier of the IMM is disrupted, the mitochondria
become uncoupled, and even glycolytically derived ATP
is hydrolysed, as the ATP synthase reverses in the
absence of a membrane potential or pH gradient.
The main triggers for opening of the mitoPTP are high
Ca2+, ATP depletion, and oxidative stress (ROS).
During ischemia, these stresses might not open the pore
because the pH is low as a result of lactic acid
accumulation (Suleiman et al., 2001). pH below 7
strongly inhibits pore opening by the protons competing
with Ca2+ for the binding sites at the ANT. With the
reperfusion, a further inﬂux of Ca2+ into theMMoccurs,
a burst of ROS is produced, and the pH returns to pre-
ischemic values as the lactate is washed away. The high
Ca2+ is the main responsible for opening the pore. The
route of Ca2+ entry into the mitochondria under
conditions of hypoxia or ischemia, surprisingly, is
not the Ca-uniporter (ruthenium red does not inhibit
the Ca2+ accumulation), but the Na/Ca-exchanger
operating in the reverse mode (can be inhibited by
clonazepam), taking up 1Ca2+ ion in exchange of 2Na+
ions. The Ca-uniporter is possibly inhibited at the lower
DYm during ischemia, and the Ca2+ entry is likely to
shift from electrogenic to electroneutral (Griﬃths et al.,
1998).
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Cellular cytoprotective K+-dependent mechanisms
Cardioprotective interventions aim at preventing irre-
versible opening of the mitoPTP in order to keep the
myocytes alive that have not died during the ischemic
phase. Therefore, IPC or PPC must modify three major
pathophysiological characteristics, which are responsi-
ble for opening of the mitoPTP: high Ca2+, ROS
production, and energy depletion. Cell life is only
compatible with closed mitoPTP and restoration of the
DYm to ensure a suﬃcient proton gradient across the
IMM for energy production.
As mentioned in section ‘What makes up the mito-
chondrial permeability transition pore?’, CsA is a potent
inhibitor of mitoPTP opening and prevents consequent
cell death. FK506, like CsA, inhibits the Ca2+–calmo-
dulin regulated phosphatase calcineurin, does not inhibit
mitoPTP opening (Suleiman et al., 2001). However,
CsA has a narrow concentration range over which it is
eﬀective, and has side eﬀects that make it unsuitable for
routine therapeutic use. The side eﬀects of CsA may
derive from the inhibition of calcineurin via its complex
with the cytosolic cyclophilin-A (CyPA). Pyruvate
added to the perfusion medium, prior to ischemia and
during reperfusion, inhibits opening of the mitoPTP and
improves the recovery of heart function. Three mecha-
nisms may be responsible for the protective eﬀect of
pyruvate: (i) it increases lactic acid production and, thus,
maintains a low pH in the MM; (ii) it acts as a scavenger
of ROS; and (iii) it is an excellent respiratory fuel to
energise mitochondria and so, enhance ATP production.
Lowering the mitochondrial Ca2+ under conditions of
hypoxia-reoxygenation by aﬀecting selectively the Ca-
uniporter with derivatives of ruthenium red, and the Na/
Ca-exchanger with clonazepam, were performed on
isolated cardiomyocytes, but these drugs are not car-
dio-speciﬁc, and these studies have not been extrapola-
ted to the whole animal.
A recent development involves the ATP-dependent
inward rectifying K+ channels in IPC as well as in PPC.
Structure and pharmacological properties of the well-
deﬁned sarcoK-ATP channel and the less well-deﬁned
mitoK-ATP channel will be described in some detail
later. Here, it suﬃces to mention that both ATP and
ADP inhibit the mitoK-ATP channel, while the sarcoK-
ATP channel is inhibited by ATP and activated by ADP
(Dos Santos et al., 2002). The mechanisms for IPC and
PPC are still debated, but both sarco- and mitoK-ATP
channels are activated by multiple signaling pathways
(see Section ‘Signaling in the early and delayed cardiac
PC’). Export of K+ ions by activation of the sarcoK-
ATP channel hyperpolarises the cell, shortens the APD
and, hence, reduces cytosolic Ca2+ loading (Figure 6C).
The lower cytosolic Ca2+ is beneﬁcial for cell survival
under stress, since it reduces most cell activities and,
thereby, lowers the energy demand; it also lowers the
Ca2+ uptake into the mitochondria.
At the mitochondrial level, K+ inﬂux via the activated
mitoK-ATP channel has several eﬀects, which are
diﬃcult to distinguish form one another and to arrange
into a sequential order of appearance. Taken together,
these eﬀects are beneﬁcial for cell survival (Hausenloy
et al., 2002; Oldenburg et al., 2002). This can be shown
by the use of drugs that activate or inhibit the mito
K-ATP channels (Table 1). Activating drugs mimic the
IPC eﬀects, while inhibiting drugs abrogate the beneﬁ-
cial eﬀects of both IPC and PPC. But the interpretation
of the experimental data is again diﬃcult, because most
of the drugs are not highly speciﬁc in targeting the
mitochondrial channels, but also aﬀect diﬀerent enzyme
Table 1. Pharmacological properties of native tissue and deﬁned, heterologously expressed K-ATP channels assessed by current measurements or
by mitochondrial ﬂavoprotein ﬂuorescence (as indicator for channel activity)
Present in tissues
Molecular
channel
composition
(Kir6/Sur)4
Cell
expression
system Diazoxide Pinacidil P1075 Glibenclamide 5HD HMR1098 MCC134
Not identiﬁed in
tissue
Kir6.1
Sur2A
HEK293 NE A A I NE NE ND
Vascular smooth
muscle
Kir6.1
Sur2B
HEK293 A A A I NE NE A
Cardiac sarcolemma Kir6.2
Sur2A
HEK293;
Cos1; Xeno-
pus oocytes
NE A A I NE I A
Non-vascular
smooth muscles
Kir6.2
Sur2B
HEK293 NE A A I NE NE A
Pancreatic beta-cells Kir6.2
Sur1
HEK293;
Cos1
A A A I I I I
Amphibian retinal
glial (Mu¨ller) cells
Kir6.1
Sur1
HEK293 A A NE I I NE ND
Mitochondria Unknown A A NE I I NE I
Abbreviations: A, activation; I, inhibition; NE, no eﬀect; ND, not determined.
Data from the literature: Gribble et al. (1998); Shindo et al. (2000); Liu et al. (2001); Marban (2002); Eaton et al. (2002); Sasaki et al. (2003);
Seino and Miki (2003); Singh et al. (2003).
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systems including components of the respiratory chain.
In addition, it was hypothesised that under ischemic
conditions when MM Ca2+ increases, the ANT itself
may also function as a K+ ion selective channel
(Halestrap et al., 2002). Pyrophosphate (PPi) is believed
to compete for the nucleotide binding sites at the ANT,
and, when bound, induces the K+ conductivity. PPi
accumulates in the MM where Ca2+ is increased,
because Ca2+ is a strong inhibitor of the matrix enzyme
pyrophosphatase.
The main eﬀect of K+ entry, by which ever route,
seems to be the volume regulation of the MM (Fryer
et al., 2000; Dos Santos et al., 2002; Halestrap et al.,
2002). K+ inﬂux induces a moderate MM swelling by
10–40% due to concomitant osmotic water uptake. Two
situations may be distinguished. First, in not severely
stressed mitochondria, the matrix swelling is small, but
the increased K+ level prevents, or reduces, subsequent
swelling during ischemia. This ensures that the mitoPTP
protein complex remains functional for high energy-
phosphoryl transfer and is not destabilised by space
expansion as would occur when the MM shrinks. A
further protective eﬀect consists in the slight, but
signiﬁcant, reduction of the DYm when the MM K+ is
increased. The lower DYm reduces the electrogenic
driving force for Ca2+ uptake through the uniporter
during the ischemic period (Murata et al., 2001). Taken
together, K+ inﬂux into the MM prevents the mito-
chondria from turning into a destabilised state prone to
mitoPTP opening. Second, in severely stressed mito-
chondria with high Ca2+ overload, shrunken MM
volume and expanded MIMS, the mitoPTP is still
closed, but its translocator function may be compro-
mised. The mitoPTP protein complex is physically
destabilised by the MIMS expansion, and the pore
would open as soon as reperfusion should start (Fig-
ure 6B). Under these conditions, K+ inﬂux may still
prevent pore opening and restore its proper translocator
function by inducing signiﬁcant swelling of the MM,
reduction of the intermembrane space and concomitant
stabilisation of the mitoPTP protein complex. Ca2+
inﬂux is inhibited by the lower DYm, and excess Ca2+
leaves the MM via the Na/Ca-exchanger into the
cytosol, where the free Ca2+ is low, because of APD
shortening and membrane hyperpolarisation due to the
activation of the sarcoK-ATP channels (Figure 6C).
If the K+ inﬂux into the MM, stimulated by IPC or
PPC, successfully prevented the opening of the mito-
PTP, the DYm is also preserved and ready to maintain
oxidative energy production upon reoxygenation. Even
after a brief opening of the mitoPTP, K+ inﬂux may be
able to preserve the DYm from total collapse, and
restore it suﬃciently to allow ATP generation during
reoxygenation, which by binding to the ANT induces
closure of the open pore. The stabilisation of the DYm
by K+ inﬂux represents an important contribution to the
cardioprotective potency of IPC and PPC. Without
conservation of the DYm, cytotoxic amounts of ROS are
produced by the uncoupled respiratory chain during
reoxygenation (confer Figure 6B and C). However, K+
inﬂux into the MM can exert the cardioprotective eﬀects
only as long as the OMM remains intact. Loss of
cytochrome-c through a disrupted OMM causes irre-
versible respiratory inhibition. Since the molecular
identity of the mitoK-ATP channel is not yet estab-
lished, the question cannot be resolved at present,
whether it is physically linked to the mitoPTP protein
complex, or whether it exerts its control over the pore
opening only indirectly via changes of K+ ion ﬂuxes and
matrix volume.
Cellular cytoprotective K+-independent mechanisms
More recently it was recognised that many of the KCO
as well as some of the inhibitors, aﬀect the myocytes by
channel-independent targets (Hanley et al., 2002a, b;
Dzeja et al., 2003). During the ischemia-reperfusion
challenge, the adenine nucleotide homeostasis depends
critically on the activity of nucleotide-metabolising
enzymes, and the oxidative stress relates to the rate of
dehydrogenase-catalysed reactions. Protection of mito-
chondria energetics, attenuation of oxidative damage,
and reduction of infarct size can be induced by KCO
such as DIAZO, pinacidil and several volatile anesthet-
ics. Some of these eﬀects were shown to be independent
of mitoK-ATP channel activation. In fact, several
enzymatic targets in the mitochondrial respiratory chain
could be identiﬁed for the diﬀerent drugs, which are
summarised in Figure 7.
Inhibition of the respiratory chain at diﬀerent sites
potently reduces ROS production during the reoxygen-
ation phase. Conversely, the mitoK-ATP channel inhi-
bitor 5-hydroxydecanoate (5HD) represents a short-chain
fatty acid that may serve as substrate for the acyl-CoA
synthase. The acyl-CoA ester 5HD-CoA may represent
the active form of 5HD. The further metabolism of
5HD-CoA circumvents the inhibitory eﬀect of DIAZO
on the succinate dehydrogenase of complex-II, which
links the TCAC to the respiratory chain (Figure 7). The
increased supply of electrons via ETF (electron transfer
factor) to ubiquinone (Q) at the ﬂavoprotein level of
acyl-CoA dehydrogenase, indeed, was shown to reverse
the DIAZO-induced attenuation of ROS production.
Thus 5HD is able to counteract the cytoprotective
eﬀects of DIAZO as far as these eﬀects operate via the
respiratory enzyme cascade. The PC induced by pinaci-
dil and volatile anesthetics may, in part, also be
operating by inhibition of the respiratory complex-I,
which is sensitive to 5HD. On the other hand, the KCO
nicorandil (a pyridyl nitrate), which can also produce
PPC, is known to liberate NO, a potent inhibitor of the
complex-IV. As the complex-IV target lies downstream
of the electron acceptor Q, the eﬀects of nicorandil
should not be completely reversible by 5HD. Carvedilol
used in the treatment of congestive heart failure and MI,
is a beta1-, beta2- and alpha1-adrenergic receptor
blocker with potent antioxidant properties (Oliveira
et al., 2001). It protects myocardial function from
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oxidative damage during ischemia-reperfusion by inhi-
biting the cardiac exogenous NADH dehydrogenase,
which is a powerful generator of superoxide radicals
located in the IMM. Furthermore, carvedilol also acts as
a weak protonophore increasing the permeability of the
IMM to protons, but not to K+, and thus stimulates
respiration. Both eﬀects are independent of the mitoK-
ATP channel and cannot be blocked by 5HD.
It needs emphasising that these eﬀects on the mito-
chondrial redox enzyme system occur under therapeu-
tically relevant concentrations. On balance, it seems that
PPC depends on both eﬀects on the mitoK-ATP channel
(with a distinct molecular identity, or connected to the
mitoPTP protein complex) and on channel-independent
targets, coupled to the mitochondrial energetics ma-
chinery.
ATP-sensitive potassium channels
Subunit organisation of the K-ATP channels
Ligand-gated K-ATP channels belong to the voltage-
independent inward rectifying K-channel superfamily
with over 60 members (Meneton et al., 1998). K-ATP
channels were ﬁrst discovered in the sarcolemma (sar-
coK-ATP channel) of cardiac myocytes (Noma, 1983)
and were later found in many other tissues (for reviews
see Babenko et al., 1998; Seino, 1999; Seino and Miki,
2003). Beside at the cell surface, K-ATP channels were
also found in the mitochondria (Inoue et al., 1991,
Paucek et al., 1992; Suzuki et al., 1997). K-ATP chan-
nels are thought to be involved in linking the cell
metabolic state to the membrane potential, thus regu-
lating a variety of cellular functions including insulin
secretion from pancreatic beta-cells, glucose uptake in
skeletal muscle, excitability of skeletal and cardiac
muscles and neurons, K+ recycling in renal epithelia
and cytoprotection in cardiac and brain ischemia.
The activity of K-ATP channels is mainly regulated
by intracellular ATP and ADP, in particular by MgADP
and the ATP/ADP ratio (Seino and Miki, 2003). An
increase in the ATP/ADP ratio closes, while a decrease
of this ratio opens the K-ATP channels. The functional
role of K-ATP channels has best been characterised in
pancreatic beta-cells (Seino et al., 2000). Increased
glucose metabolism in beta-cells induces an increase in
cytosolic ATP, which closes the K-ATP channels and
depolarises the cell membrane leading to the opening of
the voltage-dependent L-type Ca-channels. Consequent-
ly, the cytosolic calcium concentration rises and thus
triggers exocytosis of the insulin-containing granules.
Beyond the endogenous regulation of the gating
mechanism by nucleotides, K-ATP channels can be
pharmacologically targeted by both activators and
inhibitors. Sulfonylureas such as tolbutamide and gli-
benclamide, in clinical use for the treatment of non-
insulin-dependent diabetes mellitus long before their
targets were recognised, stimulate the insulin secretion
by closing the K-ATP channels in the pancreatic beta-
cells directly. This implies that the sulfonylurea receptor
is the K-ATP channel itself, or that it is a regulatory
protein associated with the channel. The pancreatic
plasma membrane K-ATP channel and its regulatory
subunit were ﬁrst cloned in 1995 (Inagaki et al., 1995;
Aguilar-Bryan et al., 1995). This allowed to establish the
Fig. 7. Scheme with sites of action of drugs and some general inhibitors of the mitochondrial respiratory chain. Lines with blunted ends (=)
indicate inhibition. Pinacidil and the volatile anesthetics inhibit the NADH:ubiquinone oxidoreductase of complex-I. Halothane also inhibits the
succinate dehydrogenase of complex-II. 5HD serves as substrate for the acyl-CoA synthase, and the main product, 5HD-CoA (an acyl-CoA ester)
may serve as substrate acyl-CoA dehydrogenase or 5HD-CoA may inhibit this dehydrogenase. Nicorandil inhibits the electron transport via the
production of NO at comlex-IV. CN), cyanide ion; CO, carbon monoxide; Cyt-C, cytochrome-c; ETF, electron transferring ﬂavoprotein; 5HD,
5-hydroxydecanoate; 5HD-CoA, 5-hydroxydecanoyl-CoA; NO, nitric oxide; NO2, nitrous oxide; Q, ubiquinone. Discussion in the text (modiﬁed
from Hanley et al., 2002a, b).
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K-ATP channel organisation as a 4:4 stoichiometric
hetero-octamer comprising two types of subunits, four
pore-forming Kir6.0 (either Kir6.1 or Kir6.2) subunits
and four regulatory sulfonylurea receptor (Sur) subunits
(Sur1 or Sur2), which are structurally not related to one
another (Clement et al., 1997; Shyng and Nichols, 1997).
The mapping of the Kir6 and Sur genes to human
chromosomes showed their pairing, Kir6.2 and Sur1 are
both located on the short arm of chromosome-11
(11p15.1) while Kir6.1 and Sur2 are in position
12p11.23 (Inagaki et al., 1995a, b). Why these genes
are clustered into pairs is unknown, especially since the
Kir6.2 subunit appears to pair with both Sur1 or Sur2
subunits expressed in diﬀerent tissues. It does, however,
suggest they may have derived from a fused ancestral
gene that has been split and subsequently duplicated
(Babenko et al., 1998).
The Kir6.0 pore protein belongs to the inward
rectifying Kir family with 15 members containing two
putative transmembrane domains (TMS) and a con-
served H5 region with the sequence Gly-Phe-Gly con-
ferring the speciﬁcity for K+ ion translocation (Meneton
et al., 1999). In all other pore-forming K-channel
subunits the K+ ion ﬁlter depends on the sequence
Gly-Tyr-Gly, instead. Four subunits together form a
pore. Kir6.0 channels are unique in that they require a
structurally unrelated regulatory subunit in order to
form a functional channel (Babenko et al., 1998). The
rat Kir6.1 and Kir6.2 proteins contain 424 and 390
amino acid residues with corresponding molecular
weights of 48 and 44 kDa, respectively, and share 71%
sequence identity (Seino, 1999). Both N- and C-termini
are located at the cytosolic side of the cell membrane.
Potential phosphorylation sites for protein kinase-A
(PKA) and PKC are located in the intracellular C-
terminal region.
Sur1 binds sulfonylurea with high aﬃnity in the
nanomolar range while Sur2 exhibits a 500 times lower
aﬃnity. The rat Sur1 and Sur2 proteins have 1581
(177 kDa) and 1545 (174 kDa) amino acid residues and
share 68% sequence identity (Seino, 1999). Both pro-
teins contain three transmembrane domains, TMD0
with ﬁve, TMD1 and TMD2 each with six transmem-
brane segments. They belong to the ATP cassette
protein family with two intracellular nucleotide binding
domains (NBD), NFD1 located within the loop between
TMD1 and TMD2, and NBD2 located in the C-
terminal region. The N-terminus lies extracellularly.
The Sur proteins have several extracellular glycosylation
sites and several intracellularly located phosphorylation
sites for PKA and PKC. Two major splice variants are
derived from the Sur2 gene: the originally cloned Sur2,
later renamed Sur2A, and Sur2B, which diﬀers by 42
amino acids in the C-terminus from the originally cloned
Sur2, later renamed Sur2A. However, Sur2B shares
these 42 amino acids with Sur1 (Seino and Miki, 2003).
Further minor splice variants of both Sur1 and Sur2
have also been identiﬁed. A functional channel may vary
in molecular weight between 872 and 900 kDa accord-
ing to its protein subunit composition, and glycosylation
seems to further increase it up to around 950 kDa.
However, the intricate interaction between the Kir6.0
channel and the regulatory Sur subunits and their
phosphorylation pattern for maximal activity has not
yet been unravelled.
Molecular and functional diversity of the K-ATP channels
The functional diversity of the K-ATP channels results
from their heteromeric assembly of Kir6.0 and Sur
subtypes (Seino and Miki, 2003). The Kir6.1-based
channels diﬀer from the Kir6.2 channels mainly by their
smaller unitary conductance of around 30 pS as opposed
to 70–90 pS. The three main regulatory Sur subunits
(Sur1, Sur2A and Sur2B) display in addition to their
diﬀering aﬃnity for sulfonylureas (high with Sur1 and
low with Sur2A and Sur2B), a rich pharmacological
spectrum, which is used for tissue-speciﬁc channel
characterisation. By heterologous expression of Kir6.0
and Sur subunits in diﬀering combinations, diﬀerent
types of K-ATP channels can be reconstituted with
distinct electrophysiological properties and varying
nucleotide and pharmacological sensitivities. Table 1
lists the subunit combinations, which were expressed
in diﬀerent cell systems, and their identiﬁcation by
immunohistochemistry or as functional channels in
diﬀerent tissues (literature given in Table 1). Kir6.1/
Sur2A was not found in any tissue so far, nor has the
molecular identity of the mitoK-ATP channel been
established yet. Current activity of surface K-ATP
channels can be measured directly by the whole-cell
patch-clamp method while the changes of intrinsic
ﬂavoprotein (succinate-, glycerol-3-phosphate- and a-
cylCoA-dehydrogenases) ﬂuorescence reﬂect the redox-
state coupled to the mitoK-ATP channel activity (Liu
et al., 2001).
Table 1 further summarises the pharmacological re-
sponses of channel activity assessed in the presence of
three channel openers (DIAZO, pinacidil, P1075) and
three inhibitors (glibenclamide, 5-hydroxydecanoate
(5HD), HMR1098). The inhibitory action of the latter
three compounds is usually tested on DIAZO- or
pinacidil-induced K-ATP channel activity. Aprikalim
(a thioformamide, not listed in the table) is a non-
selective KCO. MCC134 derived from aprikalim was
ﬁrst recognised as a vascular relaxing agent (Shindo
et al., 2000), but was subsequently shown to diﬀerently
aﬀect channels with either Sur1 or Sur2 subunits.
MCC134 activates surface K-ATP channels comprising
Sur2A or Sur2B, albeit in combination with either
Kir6.1 or Kir6.2, while, at the same time, it inhibits both
the pancreatic type channel with Kir6.2/Sur1 as well as
the mitoK-ATP of unknown composition (Liu et al.,
2001; Sasaki et al., 2003). The same Sur subunit
speciﬁcity also applies to 5HD, which inhibits the
recombinant Kir6.2/Sur1 channel with similar potency
as native mitoK-ATP channels (Liu et al., 2001), while
leaving the surface channels with either Sur2A or Sur2B
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unaﬀected. 5HD also blocks mitoK-ATP channels
reconstituted in liposomes and in isolated mitochondria
with similar potency (Jaburek et al., 1998). No channel
subunit speciﬁcity can be attributed to the KCO P1075
since it activates all recombinant combinations but
inhibits Kir6.1/Sur1 as well as the native mitoK-ATP
channel. The identical pharmacological proﬁle of mitoK-
ATP channels tested in isolated cardiomyocytes with
various activators and blockers, indicates that the mito
K-ATP channel closely resembles the recombinant
Kir6.1/Sur1 channel (Table 1).
The Kir6.1 gene is ubiquitously expressed with higher
levels in the heart (Inagaki et al., 1995a, b) and its
protein was localised in skeletal muscle by immunogold
staining at the inner mitochondrial membrane (Suzuki
et al., 1997). Sulfonylureas inhibit non-speciﬁcally all
types of K-ATP channels by binding to the regulatory
Sur subunits. With a ﬂuorescent derivative of glyburide,
another sulfonylurea, a 63 kDa protein in brain mito-
chondria was labeled with high aﬃnity in the nanomolar
range, which may represent the mitochondrial Sur
subunit (Bajgar et al., 2001). Despite its much lower
molecular weight than that of the known Sur subunits
(around 175 kDa), it seems to contain structural motifs
involved in drug and ATP binding similar to those in
Sur1. Using a panel of subunit-speciﬁc antisera, the
channel components Kir6.1 (48 kDa), Kir6.2 (40 kDa)
and Sur2A have recently been identiﬁed in mitochondria
of isolated adult rat ventricular myocytes by confocal
microscopy and immunoblotting of subcellular fractions
(Singh et al., 2003). Kir6.1 seems to be the predominant
pore-forming subunit while Kir6.2 is mainly localised in
the sarcolemma and only little in the mitochondria.
Combinations of these subunits with Sur2A would,
however, not explain the reported pharmacology of the
mitoK-ATP channel (Liu et al., 2001). The low sensi-
tivity to either the activator DIAZO or the inhibitor
5HD conferred on the K-ATP channels by the Sur2A
subunit argues against a primary role for the combina-
tion Kir6.1/Sur2A in mitochondria. Sur1 with a mole-
cular weight around 175 kDa has not yet been identiﬁed
in cardiac mitochondria.
The validity of the above considerations rests on the
assumption of a one-to-one stoichiometry with one type
of Kir6.0 and one type of Sur subunits. However, some
reports suggest the hetero-multimerisation of Kir6.1 and
Kir6.2 within the same channel complex (Kono et al.,
2000; Pountney et al., 2001; Singh et al., 2003) while
others do not (Seharaseyon et al., 2000). K-ATP chan-
nels with distinct isoform compositions thus regulate
diverse processes through interaction with the metabolic
environment unique for each cell type. Moreover, the
co-existence of channels with diﬀerent subunit compo-
sition in one cell (at the surface membrane as opposed to
subcellular organelles) would allow for their compart-
mental distribution with specialised functions. Indeed,
K-ATP channels have, beside in mitochondria, also
been found associated with the nuclear envelope (Ques-
ada et al., 2002).
Ligand binding and regulation of the K-ATP channels
Ligand binding and regulation of the ATP-sensitivity of
ther Kir6.0 potassium conductivity has recently been
described in detail (for review see Seino and Miki, 2003).
While all three Sur subunits bind two nucleotides at
their NBD1 and NBD2 sites (Matsuo et al., 2000),
Kir6.1 and Kir6.2 were also shown to bind one ATP per
subunit near its C-terminus causing closure of the pore
in the absence of Sur subunits (Tanabe et al., 2000;
Vanoye et al., 2002). Generally, ATP is inhibitory and
ADP stimulatory. In the intact hetero-octameric chan-
nel the Sur subunits lower the aﬃnity of Kir6.0 to ATP,
thus increasing the channel gating activity, when at low
ATP/ADP ratio, NBD1 binds ATP and NBD2 binds
MgADP. Sur2A has been shown to hydrolyse ATP at
NBD2 inducing a conformational transition, which is
thought to trigger the activity of the channel (Bieneng-
raeber et al., 2000; Zingman et al., 2002). Under normal
conditions, with cellular ATP far in excess of ADP,
MgADP dissociates from NBD2, resulting in release of
ATP from NBD1 and closure of the channel (Ueda
et al., 1999). In this way, K-ATP channels represent
enzyme multimers with the regulatory ATPase subunit
as intramolecular signaling system for nucleotide-de-
pendent channel gating.
The binding site for sulfonylurea at the Sur subunits is
still not yet deﬁned and diﬀerent Sur subunits confer
varying sensitivities to diﬀerent drugs (Seino and Miki,
2003). For example, Sur1 contains both one sulfonyl-
urea and one benzamido binding site, while Sur2 lacks
the sulfonylurea site. On the other hand, glibenclamide
comprises both sulfonylurea and benzamido moieties,
while tolbutamide has only the sulfonylurea moiety.
Nevertheless, Sur2B containing channels are also
blocked by tolbutamide indicating that the C-terminal
42 amino acids shared between Sur1 and Sur2B may be
involved. These diﬀerences could account, in part, for
the tissue speciﬁcity of the various sulfonylureas. More-
over, the stimulatory eﬀects of the KCO diaxozide and
pinacidil on diﬀerent recombinant channel species vary
somewhat in dependence of the cell system used and
whether MgADP was present during current measure-
ments. Depletion of cytosolic ATP by addition of
dinitrophenol (DNP), which uncouples oxidative phos-
phorylation in the mitochondria, also enhances the
activatory eﬀects of KCO on the surface channels
(Sasaki et al., 2003). Channel activation is usually more
pronounced with MgADP bound to NBD2. The drugs
seem to either enhance the ATP hydrolysis at NBD2 or
stabilise the MgADP bound state, or both (Moreau
et al., 2000; Matsushita et al., 2002).
In addition to the above mentioned pharmacological
proﬁles of P1075, 5HD, and MCC134 (Table 1), also the
agonist diazoxide and the antagonist HMR1098 exhibit
speciﬁcities useful for channel type characterisation.
While DIAZO strongly activates the pancreatic surface
channel and the putative mitoK-ATP channel Kir6.1/
Sur1, it only weakly stimulates the cardiac sarcolemmal
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channel requiring about 2000 times higher concentra-
tions. HMR1098 selectively blocks the cardiac sarcoK-
ATP and the pancreatic K-ATP channels. All eﬀects
reported in Table 1 are evoked at high potency with
dissociation constants between 1 and 50 lM, including
the non-speciﬁc activation of all channels by pinacidil
and non-speciﬁc inhibition by glibenclamide.
Is the sarcolemmal K-ATP channel required for PC?
Kir6.2/Sur2A, the cardiac sarcolemmal channel compo-
sition (Table 1), regulates the membrane potential
according to the cellular metabolic state. It is a weak
inward rectiﬁer during diastole and, when open, it
stabilises the resting potential and shortens APD. It is
expressed at much higher density than other K-channels
and it has been suggested to be critically involved in
myocardial ischemia and PC (reviewed by Nerbonne
et al., 2001). Given the high channel density, the APD is
expected to shorten by about 50% if sarcoK-ATP
channels are activated to only 1% of the maximal
conductance. Elevation of the ST-segment of the elec-
trocardiogram (ECG), characteristic of acute ischemia,
is presumed to result from dispersion of ventricular
repolarisation. In Kir6.2 deﬁcient mice the ST elevation
is absent, supporting the hypothesis that it is caused by
variable surface K-ATP channel activation and conse-
quent heterogeneities in repolarisation.
The surface channel activity is tightly coupled to cell
metabolism via a sequence of key enzyme activities
involving creatine kinase (CK), adenylyl kinase (AK)
and the muscle form of lactate dehydrogenase (M-LDH)
(Carrasco et al., 2001; Crawford et al., 2002a, b). In
fact, M-LDH (but not the cardiac form H-LDH) is
physically associated with its N-terminus at the Kir6.2
subunit and with its C-terminus at the Sur2A subunit,
while CK primarily interacts with the Sur2A compo-
nent. Despite high ATP levels in normal cardiomyocytes
these two enzymes regulate the sarcoK-ATP channel
activity. Under physiological conditions, CK catalyses
the production of ATP from creatine phosphate (CP)
and ADP, maintaining a high ATP/ADP ratio in the
channel microenvironment and keeping the channel
closed (ATP on both subunits Kir6.2 and Sur2A). CK
promotes Sur-ATPase cycling by removal of ADP from
the Sur subunit, thus keeping the channel closed. Under
metabolic stress induced by ischemia and/or hypoxia,
CP is the ﬁrst high energy phosphocompound to become
lowered. Lowering of the CP/ATP ratio drastically
slows the CK phosphoryl transfer activity. These
processes promote a drop in ATP synthesis with a
concomitant increase in ADP within the channel vicinity
resulting in facilitation of channel opening (ADP acting
on the Sur2A subunit). AK ampliﬁes the metabolic
signal by catalysing the reaction ATP + AMP $
2ADP. Under stress the mitochondrial ATP synthase
consumes cellular ATP and generates ADP, which is
delivered to the surface K-ATP channel through a chain
of sequential AK-catalysed phosphotransfer reactions.
Thus, the complex of the sarcoK-ATP channel with
CK, M-LDH, and AK allows for highly regulated
transduction of the metabolic status into membrane
excitability.
The increased K+ eﬄux stabilises the membrane
potential at a more negative level and shortens APD
resulting in a lower Ca2+ inﬂux. This may protect the
myocyte against hyperactivity and irreversible cell dam-
age during the ischemia-reperfusion phase. Kir6.2-/-
knockout mice display a phenotype of decreased toler-
ance to stress, reduced exercise capacity, impaired
intracellular Ca2+ handling, increased susceptibility to
fatal arrhythmia under sympathetic stimulation, and
failure in developing cardioprotection by precondition-
ing (Seiko and Miki, 2003; Bienengraeber et al., 2003).
Kir6.1 deﬁcient mice do not show any of these eﬀects.
The myocardial infarct size of wild-type mice with IPC
before test ischemia was signiﬁcantly smaller than in
wild-type mice without IPC, while the Kir6.2-/- mice
were resistant to the beneﬁcial eﬀects of IPC. Myocytes
from animals lacking the surface K-ATP channels have
an intact ﬂavoprotein ﬂuorescence response to DIAZO.
Treatment with HMR1098, the sarcoK-ATP channel
blocker, but not 5HD (speciﬁc for blocking the mitoK-
ATP channels) produced an impairment of the contrac-
tile function (negative inotropy) in wild-type hearts
comparable to that of knockout hearts (Suzuki et al.,
2002). The reduction in contractile function by the KCO
pinacidil was equally abrogated in mice lacking Kir6.2.
At face value, these data indicate that the sarcoK-
ATP channels are indeed prominent in modulating
ischemia-reperfusion injury in the mouse. The rapid
heart rate of the mouse (over 600 beats/min) may
magnify the relative importance of sarcoK-ATP chan-
nels during ischemia, prompting caution in the extra-
polation of this conclusion to larger mammals. In larger
animals, including humans, with heart beat rates below
200, the sarcoK-ATP channels may not be important for
PC. Furthermore, the conclusion hinges on the pre-
sumption that ischemic injury is not worse in the
knockout than in the wild-type mice. Indeed, this
appears not to be the case (Sasaki et al., 2003). During
ischemia, hearts from the knockouts developed contrac-
tures more intensely and more rapidly than those from
controls. In addition, functional recovery was much
worse in the Kir6.2 knockouts in the absence of any PC
stimulus. Thus, knockout of surface K-ATP channels
might artefactually enhance ischemic injury and cancel
the eﬀect of IPC. This undermines the conclusion that
the sarcoK-ATP surface channels are primarily respon-
sible for cardioprotection by IPC. Additionally, it
reminds one to exert caution in data interpretation
when gene disrupting technology is used for elucidation
of functions depending on a complex cellular signaling
network. The direct link with metabolism is underscored
by the observation that the knockout of M-CK or AK
genes (which encode the major cardiac creatine kinase
and adenylyl kinase isoforms) impairs proper signal
communication to sarcoK-ATP channels, resulting in
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abnormal regulation of membrane excitability (Bien-
engraeber et al., 2003). Experimental evidence indicates
that activation of the surface K-ATP channels is
causally related to ischemia-reperfusion induced ar-
rhythmias and may contribute, among other protective
mechanisms, to the delayed phase of cardioprotection.
Is the mitochondrial K-ATP channel playing the main role
in PC?
If the mitoK-ATP channel exists as a distinct molecular
entity, the answer is yes. The receptor-mediated activa-
tion of mitochondrial protective mechanisms via distinct
signaling pathways involving mitochondrion-targeted
PKC isoforms (section ‘Memory, redundancy, and
speciﬁcity in PC’) before the test ischemia, favours the
existence of a phosphorylatable channel protein at the
mitochondrial membranes. Several KCO similarly aﬀect
the sarco- and the mitoK-ATP channels including
pinacidil (a cyanoguanidine), cromakalim (a benzopy-
ran) or diethylaminoethylbenzoate. The same holds true
for channel inhibitors such as ATP and glibenclamide.
Interestingly, some agents display opposite eﬀects,
namely activation of the sarcoK- and inactivation of
the mitoK-ATP channel, these include ADP, MCC134
and long-chain fatty acid CoA esters (Grover and
Garlid, 2000; Liu et al., 2001). The pharmacological
similarities suggest grossly similar protein structures
between the two types of channel. On the other hand,
the dissimilarities with certain agents may not be
surprising in view of the diﬀerences in the Sur subunits,
which comprise the pharmacological target sites of the
channels; the Sur2A of the sarcoK-ATP channel has a
molecular weight of around 175 kDa and the putative
Sur subunit of the mitoK-ATP has one of only 63 kDa
(see Section ‘Subunit organisation of the K-ATP chan-
nels’).
The diﬀerent pharmacological properties allowed to
diﬀerentiate the individual contributions by the sarco-
and the mitoK-ATP channels to PC (reviewed by
Nakano et al., 2000). Using the selective mitoK-ATP
channel inhibitor 5HD and activator DIAZO, this
channel was shown to be predominantly important for
the early phase of PC (Garlid et al., 1997; Liu et al.,
1998). Since inhibition of signaling upstream of the
mitoK-ATP channel abolishes subsequent PC, the
channel was considered to represent the mitochondrial
end eﬀector (Hausenloy et al., 2002; Oldenburg et al.,
2002). However, protection from PC can also be aborted
when a mitoK-ATP channel blocker is present only
during the lethal ischemic phase, which suggests that the
channel can function as mediator, remaining continu-
ously active during ischemia. In addition, activation of
mitoK-ATP channels by DIAZO was also shown to
induce the liberation of moderate amounts of ROS from
the mitochondria. As this eﬀect could be blocked by
5HD, the mitoK-ATP channel may function as signal
transducer or as trigger for ROS-induced PC. The ROS
production is apparently a direct result of K+ inﬂux into
the MM because the potassium ionophore valinomycin
can mimic the DIAZO-induced ROS production. Inter-
estingly, the eﬀect of valinomycin cannot be inhibited by
5HD, which would be expected since valinomycin does
not use the mitoK-ATP channel to promote K+ move-
ment. Thus K+ inﬂux into MM seems to be the primary
mediator for moderate ROS production.
Taken together, the mitoK-ATP channel may serve at
the same time as trigger, mediator and end eﬀector,
possibly depending on the type and strength of stimulus,
and the time point in the PC process. During the test
ischemia, a positive feedback loop comprising PKC,
mitoK-ATP channel, and ROS seems to be operative
(Figure 3). This view does not preclude the possibility
that pharmacological KCO may exert additional cyto-
protective eﬀects by interference with enzymes of the
respiratory chain and other ROS producing enzymes.
Possible clinical relevance of K-ATP channels
An interesting aspect with regard to human infarct
susceptibility is the gender-speciﬁc diﬀerence in expres-
sion of the surface Kir6.2/Sur2A channel found in
guinea-pigs (Ranki et al., 2001). Female hearts comprise
at least three times more protein of both channel
subunits in Western blots than those of males. The
KCO pinacidil evoked an outﬂow current in isolated
myocytes over twice as high in females than in males.
Since the single channel properties were almost identical
between the two genders, this ﬁnding conﬁrms that the
higher current density in female myocytes reﬂects
the larger number of functional K-ATP channels in
the sarcolemma. Thus IPC, but in particular also
pharmacological interventions, which activate the sar-
coK-ATP channels, strengthen the resting potential,
shorten the APD and consequently prevent the myocyte
from Ca2+ overloading (see Figure 6B). This ties in with
the fact that isolated cardiomyocytes from female hearts
are more resistant to ischemia-reperfusion induced Ca2+
loading compared with myocytes from male tissue.
Bearing in mind the lower plasma levels of estrogen in
men of around 4 vs. 8 pg/ml in women, the results from
the guinea-pigs would suggest that estrogens aﬀord a
cardioprotective eﬀect by induction of a higher sarcoK-
ATP channel expression. This concept is supported by
the ﬁnding that in female guinea-pigs, but not males,
ageing is associated with a decrease in number of the
surface channels. In humans, a postmenopausal de-
crease of the sarcoK-ATP channels may be implicated
by the observed postmenopausal increase in prevalence
of cardiovascular disease in women (Rich-Edwards and
Hennekens, 1996; Ranki et al., 2002).
In a recent report, adult (aged below 56) and senescent
(aged above 64) patients of either gender, undergoing
coronary angioplasty were treated with IPC of 120 s
coronary occlusion before the surgical intervention (Lee
et al., 2002). This treatment signiﬁcantly lowered the
subsequent ischemic burden assessed by ST-segment
shift, chest pain score, and myocardial lactate extraction
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ratios in the adult group, but not in the senescent group.
The impaired preconditioning responsiveness in the
elderly patients was reversed by nicorandil (KCO)
administration at a dose with no nitrate eﬀect, or with
an ischemic period lengthened to 180 s. The nicorandil-
induced cardioprotection was abolished by co-adminis-
tration of glibenclamide (unspeciﬁc K-ATP channel
inhibitor) in both groups. The results suggest that the
impaired PC response in the elderly patients was
associated with some defects in the signal transduction
for activation of the K-ATP channels, either mito- or
sarcoK-ATP channels or both.
Anesthetic preconditioning: a paradigm for
pharmacological PC
Three groups of anesthetics including volatile anesthe-
tics, opioids, and ethanol-based hypnotics (chloral
hydrate, a-chloralose) were found to elicit precondition-
ing in cardiac tissue (Zaugg et al., 2002a, b), and the
preconditioning-related characteristics of these agents
were recently reviewed (Zaugg et al., 2003b). From a
clinical point of view, volatile anesthetics and opioids
are the most frequently used anesthetics in patients with
a great potential to prevent or attenuate perioperative
ischemic events in the myocardium (Zaugg et al.,
2003a). Since volatile anesthetics also precondition
endothelial and smooth muscle cells (De Klaver et al.,
2002), application of these drugs may protect a wide
variety of vital organs. This concept has been recently
supported by the ﬁndings of the ﬁrst double-blinded,
placebo-controlled study on SEVO preconditioning in
patients undergoing coronary artery bypass graft sur-
gery (Julier et al., 2003). Using biochemical markers,
this study demonstrated a signiﬁcant postoperative
myocardial and renal functional improvement in SEVO-
preconditioned patients.
APC and IPC share most signaling steps involved in
the establishment of the preconditioned state including
activation of G-protein coupled receptors (Roscoe et al.,
2000; Hanouz et al., 2002), various types of interacting
protein kinases (Toller et al., 1999; Uecker et al., 2003;
Da Silva et al., 2003), ROS (Tanaka et al., 2003), and
the putative end-eﬀectors sarco- and mitoK-ATP chan-
nels, the precise sequence of which has not been clariﬁed
yet in either type of preconditioning (Figure 8). None-
theless, recent studies revealed distinct diﬀerences in the
cardioprotective phenotype between IPC and APC.
These comprise a diﬀerential translocation and phos-
phorylation of PKC isoforms (Uecker et al., 2003) as
well as a distinct activation pattern of mitogen-activated
Fig. 8. Simpliﬁed scheme of signaling circuits potentially involved in the early phase of preconditioning by activation of the mitoK-ATP channel
by volatile anesthetics (VA). Surface G-protein coupled receptors may signal via diﬀerent classes of G-protein Gas, Gai, Gaq, Gbc. The main
routes of activation by VA involve the Gai-coupled adenosine receptor and the production of nitric oxide (NO), probably by modulation of NO
synthase (NOS) activity. These two signaling pathways converge at the level of the protein kinase-C (PKC) although alternative routes for NO via
reactive nitrogen oxide species (RNOS) may be operative as well. Lines with blunted ends (=) indicate inhibitors used. Most inhibitors partially
reduce the myocyte protection by VA. The PKC inhibitor chelerythrine (CHE) and the mitoK-ATP channel blocker 5-hydroxydecanoate (5HD)
completely inhibit cardioprotection by VA. The adrenergic receptor blockers prazosin and propranolol, and the sarcoK-ATP channel blocker
HMR-1098 have no eﬀect. Diazoxide selectively activates the mitoK-ATP channel and aﬀords cardioprotection. Ad-R, adenosine receptor;
DAG, diacylglycerol; DPCPX, speciﬁc adenosine-1 receptor blocker; IP3, inositoltrisphosphate; L-NAME, N(G)-nitro-L-arginine methyl ester;
L-NIL, L-N6-(1-iminoethyl)lysine; MnTBAP, ROS scavenger; MPG, N-(2-mercaptopropionyl)glycine; PLC, phospholipase-C; PTIO, nitric
oxide scavenger; PTX, pertussis toxin; ROS, reactive oxygen species; SNAP, NO donor; SPT, 8-sulfophenyl theophylline. Our results indicate
that the adrenergic receptors and the sarcoK-ATP channels may not play a predominant role in VA-induced early PC. Adapted from Zaugg et al.
(2002b).
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protein kinases (Da Silva et al., 2003). In addition,
trigger-dependent diﬀerences in gene expression proﬁles
between APC and IPC were recently detected in our
laboratory (unpublished results). As to whether this
trigger-dependent transcriptome variability is responsi-
ble for the previously reported diﬀerences in the memory
phase of early and delayed cardioprotection between
APC and IPC (Toller et al., 1999; Kehl et al., 2002;
Tonkovic-Capin et al., 2002) will need further investi-
gation. Apart from direct preconditioning eﬀects on
cardiomyocytes, activation of stretch-dependent gado-
linium sensitive ion channels (Piriou et al., 2000) as well
as inhibition of leukocyte adhesion were further iden-
tiﬁed as protective mechanisms associated with APC
(Laude et al., 2002).
Conclusions and outlook
An enormous wealth of facts concerning the cellular
mechanisms responsible for IPC and PPC have been
published and make it diﬃcult to see the wood for all
the trees. We are, however, at an exciting time, which
allows some pieces of the puzzle to be put together. IPC
can be elicited by so many diﬀerent primary messengers
including adenosine, catecholamines, and peptides and
proteins such as BNP and erythropoietin. Correspond-
ing to this variety of primary messengers, the signaling
for PC comprises signiﬁcant redundancy. This redun-
dancy may testify to its very early evolutionary deve-
lopment as a basic adaptive cellular defense against
various types of stress. These signals, beside inducing
PC, have a multitude of additional eﬀects not only on
the heart, but on the whole organism (Figures 4 and 5)
including remote PC in other hypoxia-sensitive organs.
Speciﬁcity in PC signaling is only acquired by recruiting
speciﬁc PKC isofomrs to structure-related signaling
modules at the target sites. The key players in the
decision on death or life for the cell, are the mitochon-
dria. All mechanisms for cardioprotection converge on
the mitochondrial permeability pore and try to keep this
pore closed. Opening of the pore, irreversibly entails cell
death. The main component in keeping the pore closed
appears to be preservation of the inner mitochondrial
membrane potential, and reduction of mitochondrial
Ca2+, thus ensuring uninterrupted energy production.
This may be achieved by K+ inﬂux into the mitochon-
dria either through the mitoK-ATP channel or which
ever other K+-selective channel device.
Perhaps the most pressing task is to better characte-
rise the mitoK-ATP channel, to deﬁne its molecular
identity and its direct physical, or indirect relation to the
permeability pore. Furthermore, precise information
about protein kinase isoforms and their structural
requirements for activation is needed in order to develop
new pharmacological strategies to apply PC in patients.
A particular rewarding aspect of basic research in the
ﬁeld of PC mechanisms, is its possibility of immediate
translation of new discoveries obtained from in vitro
experiments on isolated cardiomyocytes or on the
isolated beating heart, into the clinical setting, particu-
larly the perioperative medicine.
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